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Breast cancer is the most frequently diagnosed cancer besides skin and the second leading cause 
of cancer death among American women.  Breast cancer prevention comprises all techniques that 
lower the risk for developing breast cancer, thereby lowering population incidence and mortality.  
This dissertation used breast cancer prevention clinical trials data from the National Surgical 
Adjuvant Breast and Bowel Project to evaluate important issues related to breast cancer 
prevention.  Some breast cancer risk factors are modifiable and can be changed with lifestyle 
adjustments.  For example, high body weight has been associated with increased breast cancer 
risk among postmenopausal women, but the relationship in premenopausal women has remained 
unclear.  In the first analysis, we found a significant association between overweight and obesity 
and increased breast cancer risk in premenopausal women, and a nonsignificant association 
among postmenopausal women.  Other risk factors are not modifiable and require more complex 
interventions such as chemopreventive therapies.  The Gail model is the most popular risk 
prediction model to determine who might benefit from these therapies, but it does not include 
breast density which is an established breast cancer risk factor.  In a second analysis, high breast 
density was significantly associated with increased breast cancer risk when considered with the 
Gail score, but provided only slight improvement in discriminatory accuracy.  Despite the 
 v 
success and availability of tamoxifen and raloxifene as chemopreventive agents, they have been 
underused in clinical settings.  Providing more information about these drugs may help to 
increase their popularity.  A final analysis expanded on prior findings about tamoxifen and bone 
fractures, and showed that tamoxifen reduced osteoporotic fracture risk for all subgroups of 
women.  The public health significance of this dissertation is realized in the clarification and 
expansion of knowledge surrounding important issues in breast cancer prevention for both 
clinicians and patients.  We showed that maintaining a healthy weight is likely beneficial for all 
women at high-risk for developing breast cancer, and that women receiving tamoxifen will gain 
the added benefit of fracture risk reduction.  Furthermore, among postmenopausal women, a 
single assessment of breast density does not provide substantial risk prediction improvement. 
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1.0 INTRODUCTION 
 
Clinical research has led to great improvements in the detection, diagnosis, and treatment of 
breast cancer resulting in a steady decline in mortality over the past 20 years.  However, breast 
cancer continues to be the most commonly diagnosed cancer other than skin among women1.  
Although the search for new and improved breast cancer treatment continues, it has broadened to 
include methods for breast cancer prevention.  Finding effective methods for identifying women 
at high risk for developing breast cancer, and subsequently determining safe options for lowering 
that risk, remain crucial yet challenging areas of breast cancer research. 
The objective of this dissertation was to examine some unresolved issues related to breast 
cancer prevention including the identification of women who are at high risk for developing 
breast cancer, as well as possible concomitant benefits of chemopreventive drugs.  Specifically, a 
series of three research articles addressed the following questions:  
1. Is body mass index related to invasive breast cancer among postmenopausal and 
premenopausal women at high risk for developing breast cancer? 
2. Does baseline mammographic breast density improve the predictive capability of the Gail 
model for invasive breast cancer?  
3. Is the effect of tamoxifen on both osteoporotic and all clinical fractures consistent across 
different categories of fracture risk among women at high risk for breast cancer?  
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Data from two large randomized clinical trials from the National Surgical Adjuvant 
Breast and Bowel Project (NSABP), the Breast Cancer Prevention Trial (BCPT, P-1) and the 
Study of Tamoxifen and Raloxifene (STAR, P-2), were used to address the above questions. 
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2.0 BACKGROUND 
 
2.1 BREAST CANCER 
 
2.1.1 Overview and Descriptive Epidemiology 
 
In 2012, over 226,000 women in the United States are expected to be diagnosed with invasive 
breast cancer1.  The current incidence reflects a long-term underlying increase since 1975 when 
population-based surveillance of breast cancer began.  Between 1980 and 1987, breast cancer 
incidence rates rose by about four percent per year2.  This rapid increase has been attributed to 
the growing popularity of mammography use during that time because more cancers that were 
too small to be detected otherwise were diagnosed.  There was another slight increase during the 
1990s (1.6% per year) that was likely due to the continued rise of mammographic screening in 
addition to growing rates of obesity and the use of postmenopausal hormone therapy (PHT).  In 
2002, we began to see a decline in incidence rates among postmenopausal women following the 
release of results from the Women’s Health Initiative (WHI) which revealed detrimental effects 
of estrogen plus progestin on breast cancer risk3,4.   
Breast cancer mortality also ranks high relative to other cancers.  Behind lung cancer, it is 
the second leading cause of cancer death among females.  In 2012, an estimated 40,000 breast 
cancer deaths will occur in the United States1.  Despite these statistics, research has led to vast 
improvements in breast cancer survival.  Early detection through mammography screening, 
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available and approved chemopreventive agents, and improvements in breast cancer treatment 
have led to a steady decline in death rates for breast cancer over the past 20 years.  According to 
the American Cancer Society, relative survival at five years after diagnosis is estimated to be 
89% overall.  However, survival rates are dissimilar according to stage at diagnosis with 
estimates as high as 99% for those diagnosed at an early stage with localized disease, 84% for 
regional disease, and 23% for late-stage distant disease.  Survival rates are also lower among 
younger women diagnosed before age 40 compared to older women (84% vs. 90%) and among 
African American women compared to white women (77% vs. 90%)2. 
In addition to the United States, the impact of breast cancer can be seen throughout the 
world.  Globally, breast cancer is the most frequently diagnosed cancer and the leading cause of 
cancer death among women5.  Incidence rates are generally higher in developed countries 
including North America, Australia, and Northern and Western Europe, but low screening rates 
and incomplete reporting in developing countries may contribute to the discrepancy.  Although 
recent years have brought a decline in breast cancer incidence and mortality in the United States, 
these trends are not consistent worldwide.  Breast cancer incident rates have continued to rise in 
many African and Asian countries, most likely due to changes in obesity, physical inactivity, 
reproductive patterns, and the introduction of breast cancer screening.  Furthermore, westernized 
lifestyle changes and lack of widespread breast cancer screening programs have also contributed 
to an increase in breast cancer mortality in many Asian countries5.    
There are two main characteristics of breast cancer that are often used to describe a 
diagnosis, noninvasive and invasive.  Both of these originate in the lobules which are the milk-
producing glands in the breast, or the ducts which are the tiny tubes that carry milk from the 
lobules to the nipple.  Noninvasive breast cancers are currently referred to as lobular carcinoma 
 5 
in situ (LCIS) or ductal carcinoma in situ (DCIS), and are less severe since they are confined 
within the walls of the lobules or ducts.  In fact, nearly all noninvasive breast cancers can be 
cured6.  Invasive breast cancer occurs when the cancer cells break through the glandular or ductal 
walls and infiltrate the surrounding breast tissue.  Invasive breast cancer comprises the majority 
of breast cancers diagnosed and are more severe in prognosis and survival.  Within invasive 
breast cancer, the severity is determined by the stage of the disease which is based on the size of 
the tumor, the spread of the cancer at first diagnosis, and characteristics identified through 
laboratory tests.  The stage of breast cancer can range from completely confined to the breast, to 
spreading to the surrounding tissue and lymph nodes, or to metastasizing to distant organs.  
Invasive lobular cancer is more difficult to diagnose and therefore usually presents at a more 
advanced stage than invasive ductal cancer.  However, invasive lobular cancer has been 
associated with better survival and disease-free survival than ductal cancers7,8.     
Once a diagnosis of breast cancer is made, cancer cells removed during biopsy or surgery 
are tested for estrogen receptor (ER) and progesterone receptor (PR) status.  Receptors are 
proteins found inside and on the surface of cells that can attach to certain substances that 
circulate in the blood6.  Normal breast cells have hormone receptors that attach to estrogen and 
progesterone and act as initiators for the biological chain of events for the particular hormone.  It 
is believed that when a malignant transformation of a normal breast cell occurs, the cell may 
retain all or part of the normal population of receptor sites (i.e., hormone receptor-positive)9.  If 
the cell does not retain the receptor sites, then it is no longer influenced by hormonal control 
(i.e., hormone receptor-negative).  Therefore, estrogen promotes tumor growth in only breast 
cancers that are found to be positive for hormone receptors.  Women with hormone receptor (ER 
and/or PR) positive breast cancer tend to have lower-grade tumors that grow slowly and respond 
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well to hormonal therapy, and thus have a better prognosis than women with hormone receptor-
negative cancer.  ER and/or PR-positive breast cancers account for approximately 65 percent of 
all diagnosed breast cancers and occur more frequently in older, postmenopausal women.  
Likewise, ER and PR-negative cancers are diagnosed more often in younger, premenopausal 
women.  Differences by race also exist with ER and/or PR-positive cancers being more common 
among white women compared to African American10. 
Invasive breast cancer tumors are also assessed for the human epidermal growth factor 
receptor 2 (HER2).  Normal cells have one copy of the HER2 gene on each chromosome 17, 
which instructs cells to make the growth-promoting HER2 protein.  Women with HER2-positive 
breast cancers have too many copies of the HER2 gene leading to an increased number of 
receptors at the tumor-cell surface.  This leads to excessive cellular division and the formation, 
proliferation, and survival of tumors11.  About 25 percent of invasive breast cancers test positive 
for increased levels of HER26,11.  HER2-positive cancers tend to grow and spread more 
aggressively than HER2-negative breast cancers11. 
 
2.1.2 Risk Factors for Breast Cancer 
 
Many factors have been identified that are associated with an increased risk of breast cancer.  
Some of these factors are modifiable through lifestyle changes.  However, there are also many 
strong risk factors associated with breast cancer that are not modifiable.  It is important for all 
women to be aware of breast cancer risk factors and understand the impact they may individually 
and collectively have on breast cancer risk.  Understanding why and how all risk factors (both 
modifiable and not modifiable) influence the development of breast cancer is important for 
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finding ways to reduce risk and prevent the disease.  Table 2-1 lists personal, lifestyle, 
reproductive, and medical factors that have been associated with an increased risk of breast 
cancer.  They are grouped by the strength of the association2,12.   
 
 
Table 2-1. Summary of breast cancer risk factors 
Strength of Association Risk Factor 
 
Relative Risk > 2.0 
Older age 
Family history of breast cancer (first-degree relatives) 
History of atypical hyperplasia 
Higher breast density 
Higher bone density 
 
Relative Risk ≤ 2.0 
Race 
Number of breast biopsies 
Late age (>30 years) of first live birth 
Early menarche (<12 years) 
Late menopause (>55 years) 
Nulliparity 
Never breastfed a child 
Recent oral contraceptive use 
Recent PHT use with combined estrogen and progestin 
Obesity 
Low physical activity 
Alcohol consumption 
Cigarette smoking 
 
 
 One of the most important risk factors for breast cancer is age.  A woman’s risk increases 
steadily until around the age of 85 years.  The majority of breast cancers are diagnosed among 
women over age 40 (95%), with a median age at diagnosis of 61 years2.  However, women 
diagnosed before the age of 40 often have more aggressive tumors that are unresponsive to 
treatment.  Race is another important risk factor with white women being more likely to develop 
breast cancer than African American women.  However, despite their lower incidence rate, 
African American women are more likely to die from the disease.  A positive family history of 
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breast cancer also increases the risk for developing breast cancer.  Having one first-degree 
relative (i.e., mother, sister, or daughter) with breast cancer doubles the risk and having two 
relatives increases the risk 5-fold.   
 Lifestyle factors such as alcohol use, cigarette smoking, physical activity, and obesity 
have also been studied in relation to breast cancer risk.  There is substantial evidence in the 
literature that alcohol consumption increases breast cancer risk by about 10% with one alcoholic 
beverage per day13,14.  Furthermore, alcohol may be more strongly related to ER-positive breast 
cancer than ER-negative cancers, and the relationship is more pronounced for lobular subtypes 
compared to ductal15,16.  Recent findings have also provided evidence of an increased risk for 
breast cancer among active cigarette smokers, and the risk appears to be greater with a longer 
duration of smoking years and for those who started to smoke at a younger age17-19.  Physical 
activity in the form of exercise appears to play a role in the development of breast cancer as well.  
Evidence in the literature has been somewhat inconsistent and further study is needed.  However, 
in general, increased levels of physical activity have been associated with a reduction in breast 
cancer risk15,20.  Related to physical activity, obesity has also been associated with breast cancer 
risk.  Specifically, a protective effect among premenopausal women and a detrimental effect 
after menopause has been suggested throughout the literature.  This relationship will be 
discussed further in section 2.1.3.    
 Various reproductive factors are strongly associated with an increased risk for breast 
cancer.  These include age of menarche, age of menopause, nulliparity, and age of first live birth.  
Both an early age of menarche (i.e., onset of menstruation at age 12 or younger) and an older age 
of menopause (i.e., discontinuation of menstruation at age 55 or older) are associated with an 
increased risk for breast cancer.  This increased risk is believed to relate to levels of endogenous 
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estrogen circulating in a woman’s body.  Estrogen is primarily responsible for the growth and 
differentiation of normal breast tissue, and in premenopausal women, nearly all of circulating 
estrogen is of ovarian origin.  Thus, it is believed that the risk for breast cancer is directly related 
to the cumulative number of ovulatory menstrual cycles in a woman’s life.  Also related to the 
total number of menstrual cycles throughout a woman’s lifetime is the number of times she has 
been pregnant, with an inverse relation between the number of pregnancies and breast cancer 
risk.  Moreover, the risk for breast cancer is increased for nulliparous women and those who 
experienced their first full-term pregnancy after the age of 30 years.  Breastfeeding has been 
associated with a decreased risk for breast cancer and is more protective with longer cumulative 
durations of breastfeeding21.   
 Exogenous estrogen exposure is also associated with an increased risk for breast cancer.  
PHT with combined estrogen and progestin was once commonly prescribed to alleviate hot 
flashes and osteoporosis in postmenopausal women.  However, in 2002, the WHI released results 
from a randomized controlled trial of over 16,000 women confirming that combined estrogen 
plus progestin use increased the risk for invasive breast cancer3,4.  However, the increased risk 
diminished after 5 years of stopping the combined PHT and subsequent studies found no 
increased risk with estrogen-only therapies for women post-hysterectomy22-25.  Since the original 
findings were reported, the use of this type of PHT has decreased substantially.  Studies have 
also shown a slight increase in breast cancer risk for women who take combined estrogen and 
progestin oral contraceptives; however, after 10 years of discontinuation there was no increased 
risk for invasive breast cancer26.   
 Clinical factors such as the number of previous breast biopsies, history of atypical 
hyperplasia, bone mineral density (BMD), and mammographic breast density have also been 
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associated with an increased risk of invasive breast cancer.  Unsurprisingly, since a breast biopsy 
is an indicator of previous benign breast disease, a greater number of previous breast biopsies is 
associated with an increased risk for breast cancer.  Likewise, women who have a history of 
atypical hyperplasia, which is a type of benign breast disease where there is excessive growth of 
abnormal breast tissue cells, have a risk of invasive breast cancer that is four to five times higher 
than women without such a history.  BMD is a measure of bone strength and risk of fracture that 
is positively correlated with estrogen exposure.  Thus, older women with increased levels of 
BMD have been shown to have an increased risk for breast cancer27, possibly because BMD is a 
marker of higher lifetime estrogen exposure.  Mammographic breast density is the proportion of 
the breast that is composed of glandular and connective tissue relative to fatty tissue that shows 
up as white area on a mammogram.  Many studies have found mammographic breast density to 
be a strong independent risk factor for breast cancer with an increased risk that is about three to 
five times greater in women with dense breasts compared to women with less dense or mostly 
fatty breasts28-30.  This relationship is discussed in greater detail in section 2.1.4.   
 
2.1.3 Association between Obesity and Breast Cancer Risk 
 
Obesity is defined as excessive accumulation of body fat, but is often quantified as excess body 
weight for ease of measurement.  Body mass index (BMI) is the most common measure of 
excess body weight used in epidemiologic studies.  It is calculated as weight in kilograms 
divided by height in meters squared.  Despite its ubiquitous use, BMI may not always be a 
precise measure of obesity in clinical studies.  Measurements may be inaccurate if they are based 
on self-reported data since respondents typically overestimate their height and underestimate 
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their weight, the latter being true particularly among women31.  Therefore, it is recommended 
that trained clinical staff perform measurements of weight and height.  BMI also does not 
account for losses in height caused by osteoporosis or variations in lean body mass, which can 
affect the measurement of BMI without an actual change in body fat mass.  Thus, older women 
will usually have a higher percentage of body fat at a given BMI than younger women31,32.  
Despite its limitations, BMI is quickly and easily attainable and has been deemed satisfactory for 
clinical and epidemiological purposes32.  Classifications of BMI from the World Health 
Organization are as follows:  <18.5 as underweight, 18.5-24.9 as normal, 25.0-29.9 as 
overweight, and ≥30 as obese.   
 The relationship between BMI and breast cancer has been extensively reported in the 
literature; however, conflicting and inconsistent results have led to speculation regarding its true 
nature.  Associations between obesity and breast cancer risk are believed to differ based on 
menopausal status.  Studies have identified BMI as a risk factor for breast cancer among 
postmenopausal women33-35, and as a protective factor among premenopausal women36-38.  In an 
early meta-analysis of 19 case-control and four cohort studies conducted among premenopausal 
women, Ursin and colleagues39 found a modest inverse association between BMI and 
premenopausal breast cancer.  Furthermore, a meta-analysis conducted by van den Brandt and 
colleagues in 200040 that used data from seven prospective studies supported a significant, 
inverse association between BMI and premenopausal breast cancer and a significant, positive 
association among postmenopausal breast cancer.  However, other studies have been inconsistent 
among premenopausal women and were unable to find an association35,41-43.   
 The most widely accepted explanation for the paradoxal relationship between BMI and 
breast cancer risk by menopausal status involves estrogen availability.  After menopause, most of 
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the circulating estrogen in a woman’s body comes from the aromatization of adrenal androgens 
in adipose tissue.  Therefore, excess fat results in higher circulating estrogen levels in a woman’s 
body, which stimulates the growth and progression of breast cancer.  However, in premenopausal 
women, the level of circulating estrogen is controlled by the ovaries and therefore may not be 
greatly affected by the amount of excess fat.  The estrogen connection in postmenopausal women 
is based on sound biological plausibility and clinical findings.  In 2003, the Endogenous 
Hormones and Breast Cancer Collaborative Group pooled individual data from postmenopausal 
participants of eight different prospective studies and found that controlling for serum hormone 
concentrations attenuated the positive association between an increased risk of breast cancer and 
BMI44.  Multiple hormones were tested, but the greatest effect was seen with concentrations of 
free estradiol for which the relative risk per 5 kg/m2 increase in BMI was reduced from 1.19 to 
1.02.  They concluded that the increase in risk with high BMI was due to a corresponding 
increase in estrogens44.  Furthermore, among postmenopausal women obesity has been more 
strongly related to ER-positive breast cancer than with ER-negative breast cancer thereby 
supporting the theory that greater amounts of circulating estrogen in obese women can increase 
the risk of tumor development45.   
Unfortunately, mechanisms for explaining the protective effect of obesity on 
premenopausal breast cancer are not as clear.  The principal explanation has been anovulation 
among obese women.  However, a study conducted by Michels et al.38, which used data from 
premenopausal participants of the Nurses’ Health Study (NHS) II, found that the inverse 
association between BMI and breast cancer risk was not explained by menstrual cycle 
characteristics, infertility due to ovulatory disorders, or probable polycystic ovary syndrome 
because adjustment for these factors did not attenuate the association.  Although they could not 
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measure anovulation directly, they concluded that it was unlikely that anovulation was the 
primary reason that premenopausal women with a high BMI had a lower risk for breast cancer.  
Furthermore, premenopausal breast cancers are more likely to be ER and PR-negative and 
therefore not dependent on estrogen.  When looking at premenopausal breast cancers by receptor 
status, studies have shown that obese women have a lower risk for developing ER or PR-positive 
breast cancers, but not ER and PR-negative cancers32,46.  A recent study by Harris et al.47 used 
NHS II data to look at the relationship between body fat distribution and risk for invasive breast 
cancer by subtype of cancer.  They found that among their premenopausal population, abdominal 
adiposity increased the risk of developing ER-negative breast cancer but was not associated with 
ER-positive breast cancer.  Therefore, the effect of obesity on breast cancer risk in 
premenopausal women may be acting through other pathways besides estrogen.  A recent study 
showed that women with triple-negative breast cancers (i.e., negative for ER, PR, and HER2) 
also had a high prevalence of metabolic syndrome, characterized by obesity and insulin 
resistance48.  Insulin resistance leads to hyperinsulinemia and stimulated synthesis of insulin-like 
growth factor-I (IGF-I) which both may contribute to tumor development and tumor 
growth32,49,50.  Links between these factors and obesity are being explored for biological 
mechanisms explaining the obesity and breast cancer risk relationship, particularly among 
premenopausal women50. 
Certain individual factors have been shown to affect the relationship between BMI and 
breast cancer risk.  A study from the WHI that examined obesity, body size, and the risk of 
postmenopausal breast cancer found that PHT use (either formerly or currently) attenuated the 
association of BMI and risk of breast cancer among postmenopausal women34.  The authors 
theorized that taking PHT would raise the amount of circulating estrogen in the body to such a 
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degree that any additional amount made available by the conversion of androgens to estrogens in 
adipose tissue would be negligible.  Based on their findings, they concluded that obesity 
increased risk only among postmenopausal women who had never taken PHT.  Other studies 
have supported these findings35.  Similarly, among premenopausal women, studies have shown 
that having a family history of breast cancer or a history of oral contraceptive use may attenuate 
the inverse relationship between obesity and breast cancer risk40,45. 
   When studying the relationship between BMI and breast cancer risk, detection bias 
cannot be ruled out as an explanation for inconsistent results.  Obese women are less likely to 
partake in breast cancer screening38.  Furthermore, it may be difficult to palpate lumps in obese 
women with larger breasts, 51.  Therefore, unless an obese woman is undergoing regular 
mammographic screening, cancer may go undiagnosed for some time until the tumor is large 
enough to palpate.  Cui and colleagues found that high BMI was significantly associated with a 
later stage of breast cancer at diagnosis and larger tumor size51.  They also found that this 
association was stronger among younger women compared to older women.  It is possible that if 
diagnoses are delayed among heavier women, then the detection will occur in the 
postmenopausal stage of life instead of prior to menopause, causing the association to appear 
stronger among postmenopausal women38.    
 
2.1.4 Association between Breast Density and Breast Cancer Risk 
 
Differences in breast tissue composition among women are reflected in mammography.  Fat 
appears dark on a mammogram since it is radiologically lucent, allowing x-rays to easily pass 
through.  However, connective and epithelial tissues such as those comprising milk ducts and 
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lobules are radiologically dense and block the x-rays from passing through.  Thus, they appear 
white on a mammogram.  Mammographic breast density is usually expressed as the percentage 
of breast area that is occupied by connective and epithelial tissues (i.e., the proportion appearing 
white on a mammogram)28.  There are various methods for classifying mammographic breast 
density.  Dr. John Wolfe developed the earliest classifications in 1976, and was the first to show 
the existence of a relationship between breast density and breast cancer risk.  He described four 
distinct parenchymal patterns for classification: N1 (predominantly fat), P1 (ductal prominence 
in less than one-fourth of the breast), P2 (ductal prominence in more than one-fourth of the 
breast), and DY (severe involvement with dysplasia)28,52.  Wolfe’s categories became commonly 
used for classifying breast density.  However, subsequent studies were not able to replicate and 
support Wolfe’s findings, most likely because of a lack of consistency in applying the 
parenchymal pattern classifications.  Therefore, in the United States, his classifications fell out of 
use as researchers began to look for new, more precise methods for measuring breast density.  
They began basing categorizations on quantitative estimations of the percentage of density in the 
breast instead of on strictly qualitative estimates.  Using these quantitative methods, studies 
began to consistently show a positive association between breast density and the risk of breast 
cancer, leading to the acceptance of breast density as a risk factor for breast cancer.  Women 
with high mammographic breast density were found to have a breast cancer risk that was three to 
five times larger than women with less dense breasts28-30.  Studies also found that both past and 
current breast density were associated with risk, and that although masking bias does occur it 
likely has only a small and short-lived effect28,52,53. 
     Currently in the United States, the American College of Radiology Breast Imaging 
Reporting and Data System (BI-RADS) provides a commonly used classification system of 
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breast density in clinical practice54.  It was developed to standardize mammography reporting 
terminology as a way to estimate breast density and mammography accuracy.  BI-RADS 
categories were not originally defined by percentage of density, but in 2003, quantitative 
percentage ranges were added to the descriptive categories55.  The current BI-RADS density 
classifications are defined as follows:  Grade 1 – the breast is almost entirely fat (<25% 
glandular), Grade 2 – there are scattered fibroglandular densities (approximately 25-50% 
glandular), Grade 3 – the breast tissue is heterogeneously dense, which could obscure detection 
of small masses (approximately 51-75% glandular), and Grade 4 – the breast tissue is extremely 
dense (>75% glandular).  The BI-RADS breast density classifications have been shown to have 
only moderate interobserver agreement28,55, but their widespread use and availability allow for 
convenient use in large study populations.  More consistent methods of classification include 
computer-assisted planimetry and the use of thresholding methods with digitized 
mammograms28,52; however, all of these methods, including BI-RADS, require the input of 
trained observers and are therefore subjective in nature.  Newer objective methods take the 
thickness of the breast into account to calculate volumetric breast density and appear to be more 
accurate and consistent.  They include the use of Standard Mammogram Form (SMF) on 
digitized film screen mammograms, the use of full-field digital mammography (FFDM), and the 
use of magnetic resonance imaging (MRI) and ultrasound.  However, all of these methods have 
not been studied in relation to breast cancer risk, and for those that have been studied, results are 
preliminary28,56,57.  Furthermore, methods such as MRI can be costly and may not be appropriate 
for widespread use.   
 Breast density has been associated with certain host characteristics that may also be 
related to breast cancer.  For example, BMI and percent breast density are largely interrelated 
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such that women with high BMI are more likely to have a low percent breast density.  This is 
because BMI is positively related to total breast area, which is the denominator for percent breast 
density57.  Because a high BMI may increase risk for breast cancer, especially among 
postmenopausal women, it is believed that the effect of parenchymal patterns estimated by 
percent breast density on risk will tend to be underestimated when not adjusted for BMI58.  
Preliminary studies have suggested that other measures of density, such as the absolute area of 
dense tissue or the volumetric breast density may eliminate this interrelationship.  A recent study 
using a measure of volumetric breast density through FFDM instead of percent breast density 
showed that density volume was greater in women with high BMI56.   
 In addition to BMI, high breast density is more common among white women compared 
to African-American women.  It is also associated with nulliparity, late age at first birth, and 
younger age due to breast involution and density decreases that occur with age, the greatest of 
which occur after menopause59,60.  Certain medication use has been shown to affect breast 
density as well.  For example, PHT slows normal breast involution in postmenopausal women 
and causes an increase in mammographic density in 17-73% of women.  On the other hand, both 
tamoxifen and raloxifene have been found to decrease mammographic density52.  Despite all of 
the above listed characteristics, genetic factors are believed to account for a large proportion 
(approximately 50-70%) of the variation in mammographic breast density61.  A few small studies 
that focused on mother-daughter sets, twins, and segregation analyses have supported this 
hypothesis28.  Specifically, segregation analyses suggest that a major autosomal gene influences 
breast density, with a likely Mendelian transmission of a dominant gene (possibly on 
chromosome 6).  In addition, women with BRCA1 and BRCA2 mutations have been shown to 
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have more dense breast tissue that is coarser and lower in contrast than women at low risk for 
developing breast cancer52. 
  
 
2.2 GAIL MODEL 
 
2.2.1 Background and History 
 
The Gail model incorporates a multivariate logistic regression model that was originally 
developed in 1989 by Mitchell Gail and colleagues using data from the Breast Cancer Detection 
Demonstration Project (BCDDP)62.  The purpose of the model, referred to here as model 1, was 
to estimate the probability of developing invasive or noninvasive breast cancer among women 
receiving regular mammographic screenings.  In addition to the age of the participant 
dichotomized into above or below 50 years, the model included age at menarche, age at first live 
birth, the number of previous breast biopsies, presence of atypical hyperplasia, and the number 
of affected first-degree female relatives.  The relative risks associated with these factors were 
combined with estimates of the baseline hazard rates and attributable risks in the BCDDP 
population.  Statisticians at the NSABP later modified model 1 to project the probability of 
developing invasive breast cancer only63,64.  This modification, referred to as model 2, replaced 
the breast cancer incidence rates from the BCDDP with age and race-specific invasive breast 
cancer rates from the Surveillance, Epidemiology, and End Results (SEER) Program of the 
National Cancer Institute (NCI) and used attributable risk estimates from SEER to obtain the 
baseline hazard rates.  
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 The Gail model has been validated in multiple study populations including the Cancer 
and Steroid Hormone (CASH) Study, NHS, and BCPT.  Using data from the CASH Study, Gail 
and Benichou found that model 1 overpredicted breast cancer risk in younger women65.  
Spiegelman and colleagues concluded similar findings using NHS data66.  However, both of 
these studies looked at women who were not undergoing regular mammographic screening.  
When considering women who were receiving regular screening, model 1 provided reasonable 
agreement between observed (O) and expected (E) cases in younger women (137 vs. 126.91, 
respectively)63,67.  Costantino and colleagues assessed the validity of model 2 using white women 
who were assigned to the placebo arm of BCPT63.  They found that the model was well 
calibrated in this population (E/O ratio of 1.03).  Rockhill and colleagues further assessed the 
validity of model 2 using data from white women participating in NHS to evaluate 
discriminatory accuracy in addition to model calibration68.  They concluded that model 2 was 
well calibrated (E/O ratio of 0.94) with modest discriminatory accuracy (c-statistic of 0.58).  
Although research continued for possible methods of improvement, model 2 became the most 
reliable and widely used model for risk prediction.   
The Gail model could be applied to African Americans and women of other races and 
ethnicities; however, the projections were based on assumptions instead of empirical data.  So in 
more recent years, the model was updated to provide more accurate predictions among African 
Americans69 and Asians70.  In 2007, Gail and colleagues used data from almost 2,300 African 
American women participating in the Women’s Contraceptive and Reproductive Experiences 
(CARE) Study to build a model for predicting absolute invasive breast cancer for African 
Americans.  They compared the projections from the new model with those from the previous 
model and calibrated the new model using data from African American women in the WHI.  The 
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final CARE model was more parsimonious than the original and was well calibrated with good 
agreement between the number of predicted and observed cases in the WHI population.  The 
CARE model also projected larger estimates of invasive breast cancer for African Americans 
than the prior model, which enabled more women to be eligible for and benefit from 
chemopreventive therapies and future clinical trials69.  In 2011, the model was updated to 
provide more accurate predictions for Asian and Pacific Islander American women.  Data from 
589 cases and 952 controls participating in the Asian American Breast Cancer Study were used 
to create a model, and data from Asian and Pacific Islander American participants of the WHI 
were used to assess model calibration and discrimination.  The new model was more 
parsimonious, had good fit, and gave smaller estimates of invasive breast cancer risk for Asian 
and Pacific Islander American women than the original model70.   
When model 2 was first developed, the age-specific breast cancer incidence rates were 
based on SEER data from 1983 to 1987.  Since then, breast cancer incidence rates have changed 
substantially and so the rates used in the Gail model were not representative of more 
contemporary study populations.  In 2010, Schonfeld and colleagues used more recent SEER 
rates from the 1995 to 2003 period to create an updated version of the Gail model71.  They then 
compared their updated model to model 2, which was based on the earlier SEER rates.  They 
used data from white, postmenopausal women participating in the National Institutes of Health – 
AARP Diet and Health Study, and the Prostate, Lung, Colorectal and Ovarian Cancer Screening 
Trial (PLCO).  Almost all of the follow-up for both of these cohorts occurred after 1995, which 
corresponded to the more recent SEER rates.  They found that the original Gail model based on 
the earlier SEER rates underpredicted invasive breast cancer in these two contemporary 
populations, and that using the updated SEER rates improved the calibration of the model.  Thus, 
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they showed the importance of updating risk prediction models to reflect recent trends in 
incidence rates in order to remain relevant for use in the clinical setting.  
 
2.2.2 Use in Clinical Practice and Research 
 
Many women, especially those with a family history of breast cancer, tend to overestimate their 
risk for developing breast cancer.  The Gail model was originally developed for the primary 
purpose of providing these women with a realistic estimate of their chance for developing breast 
cancer over different periods of their life65.  Women and their doctors could then use these 
individualized estimates to aid in decisions regarding the management and control of risk.  In the 
late 1990s, the NCI distributed a computer program to health care providers that computed the 
risk of invasive breast cancer based on model 2 and later posted this Breast Cancer Risk 
Assessment Tool on their website72,73.  Since then, the tool has been updated to reflect the 
modifications for African Americans and Asian Americans, and will soon be updated to reflect 
the most recent breast cancer incidence rates from SEER and specific projections for Hispanic 
women.  The tool provides an estimate of risk for developing invasive breast cancer over the 
next five years and over the lifetime of each woman if she were to live to age 90.  For 
comparison, the tool also provides the 5-year and lifetime risk estimates for a woman of the same 
age who is at average risk for developing breast cancer73.  A 5-year risk of invasive breast cancer 
of 1.66% or greater is considered to be the cut-point for identifying high versus low risk 
individuals.  Any woman with a score above 1.66% should be evaluated further to determine 
whether she would benefit from prophylactic surgeries or chemoprevention. 
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 Despite the fact that any woman can go online and calculate her own risk for developing 
breast cancer, it is important that the results are reviewed by and discussed with clinicians or 
counselors.  Understanding the concept of risk may be difficult for most of the general public.  
Therefore, it is important that each assessed woman understands that no model is perfect, and 
that there may be some personal characteristics, such as having a breast cancer gene, that could 
affect individual risk despite what was predicted by the Gail model65.  Clear communication is 
necessary so that each woman understands that although the Gail model may classify her as high 
risk, that does not mean that she is likely to get cancer in the near future, but only that her risk is 
high enough to consider some form of preventive action including chemoprevention68.   
 In addition to its recommended use in clinical practice, the Gail model has also been used 
in research to identify women with an increased risk for breast cancer.  The number of invasive 
breast cancers developed during a study affects the statistical power of the trial.  Therefore, the 
Gail model has become a useful tool in the planning of breast cancer chemoprevention studies65.  
The Gail model was used to assess eligibility for participation in both the Breast Cancer 
Prevention Trial (BCPT) and the Study of Tamoxifen and Raloxifene (STAR), which were large, 
randomized breast cancer chemoprevention clinical trials conducted by the NSABP.  The desired 
population for both trials was women at high risk for developing breast cancer, and a Gail score 
of 1.66% or higher was a criterion for eligibility.   
 
2.2.3 Limitations and Possible Improvements 
 
The Gail model is a powerful and useful tool for breast cancer risk prediction in both the clinical 
setting as a guide for counseling and risk-reduction recommendations, and in research as a 
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method to identify eligible, high-risk participants.  The model has good calibration and 
accurately predicts incidence of breast cancer in groups of women.  However, the Gail model 
does have some limitations.  As with most risk prediction models for relatively rare diseases, it 
has low to moderate discrimination (c-statistic ranging from 0.58 – 0.62)74, and therefore only 
modestly predicts incidence at the individual level.  The model may also not perform well for all 
races.  Although, it has been validated in the United States for white, African American, and 
Asian women, there remain some races for which there has been very little data such as 
Hispanics.   
It has also been suggested that different models might be better for different subgroups of 
women within races (i.e., premenopausal vs. postmenopausal) or for different types of breast 
cancer (i.e., ER-positive vs. ER-negative)75.  Chlebowski and colleagues used data from the WHI 
to validate and possibly improve the Gail model for estimating risk for invasive breast cancer by 
ER status in postmenopausal women75,76.  They determined that in their population the Gail 
model had moderate discrimination for ER-positive breast cancers (c-statistic of 0.58) and that 
adding additional risk factors did not provide a significant improvement in prediction.  However, 
they found that a more parsimonious model predicting ER-positive breast cancers in 
postmenopausal women performed nearly as accurately as the Gail model with the same 
discriminatory accuracy.  Their new model included only age, family history of breast cancer, 
and a history of a previous breast biopsy.  They suggested that this model may be more 
accessible for rapid screening and better fitting for postmenopausal women likely to be 
diagnosed with ER-positive breast cancer; however, results need to be tested among other 
populations before being accepted and put into use. 
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Many researchers have focused on whether adding additional risk factors to the Gail 
model would improve its predictive capability.  Chlebowski et al. assessed a number of personal 
characteristics such as parity, breastfeeding, smoking, alcohol, BMI, physical activity, and prior 
estrogen use and found that none added significant improvements to the model.  However, they 
did not have the ability to assess breast density.  Because breast density is a strong independent 
risk factor for breast cancer, speculation abounds regarding its use in predictive models.  Using 
data from the BCDDP, Chen and colleagues77 added a continuous measure of breast density to a 
model with weight, age of first live birth, number of affected relatives and number of breast 
biopsies.  This new model showed improved risk discrimination (c-statistic of 0.64) when 
compared to the Gail model; however, it has not been validated in different populations and a 
continuous measure of breast density may not be realistic in clinical practice.  Three other 
studies29,78,79 used data from the Breast Cancer Surveillance Consortium (BCSC), which 
comprises information from over one million women from seven mammography registries, to 
develop breast cancer risk prediction models that included traditional risk factors as well as 
breast density.  Barlow et al.78 looked at pre- and postmenopausal women separately and found 
that a model including BI-RADS breast density and hormone therapy had greater predictive 
accuracy than the same model without breast density (c-statistic of 0.63 vs. 0.60).  However, it 
was only a short-term model based on breast cancers diagnosed within one year after the initial 
mammogram.  In 2005, Tice and colleagues79 used data from one of the BCSC mammography 
registries in San Francisco and found that adding breast density to the Gail model slightly 
improved the predictive accuracy of the model (c-statistic of 0.68 vs. 0.67).  Furthermore, they 
found that a simpler model with BI-RADS breast density, age, and ethnicity performed similarly 
to the Gail model in their population.  In 2008, Tice et al.29 aimed to improve upon their original 
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findings by including data from all seven BCSC mammography registries.  This time they 
included family history of breast cancer and history of breast biopsy in addition to BI-RADS 
breast density, age, and ethnicity.  They found that the model was well-calibrated (E/O ratio of 
1.01) and had modest discriminatory accuracy (c-statistic of 0.66).  Existing literature supports 
the idea that including a measure of mammographic breast density may increase the capability of 
a model to predict risk for invasive breast cancer; however, researchers agree that these models 
need to be studied in multiple independent populations before put into clinical use. 
 
 
2.3 BREAST CANCER CHEMOPREVENTION 
 
2.3.1 History and Current Methods of Chemoprevention 
 
Chemoprevention is the use of medicines, vitamins, or other agents to delay or prevent the 
diagnosis of cancer.  Chemoprevention of breast cancer has primarily focused on the use of 
selective estrogen receptor modulators (SERMs).  SERMs are selective in that they act as 
estrogen agonists in some tissues and antagonists in others.  Therefore, they can either stimulate 
or inhibit estrogen-like action in various tissues.  Tamoxifen is the most well-known of these 
drugs.  Tamoxifen use inhibits estrogen-like action in the breast, but stimulates it in the bone and 
uterus.  This selective activity is why tamoxifen lowers the risk of incident and recurrent breast 
cancer, but increases bone density in postmenopausal women and is associated with an increased 
risk of endometrial cancer.  More recently, a second generation SERM, raloxifene, also received 
recognition for the prevention of invasive breast cancer, but only in postmenopausal women.  
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Raloxifene demonstrates anti-estrogenic activity on the breast, but unlike tamoxifen, it also has 
anti-estrogenic actions on the uterus.  Therefore, it is not associated with an increased risk of 
endometrial cancer. 
 The possible role of tamoxifen in breast cancer prevention became of great interest due to 
its success in lowering the incidence of contralateral breast cancer after adjuvant therapy.  Four 
large placebo-controlled trials designed to investigate tamoxifen for lowering the incidence of 
invasive breast cancer began around the early 1990s.  The largest of these trials was the NSABP 
BCPT80.  A total of 13,388 high-risk women were randomized and followed for an average of 4 
years at the time of the initial report.  Women were considered to be high-risk if they were 60 
years of age or older, had a 5-year predicted risk of developing breast cancer of at least 1.66% 
based on the Gail model, or had a history of LCIS.  Results showed that tamoxifen compared to 
placebo reduced the incidence of invasive breast cancer by 49% and the incidence of noninvasive 
breast cancer by 50%.  When looking at the type of invasive breast cancer, tamoxifen reduced 
the incidence of ER-positive breast cancer by 69% but did not significantly affect ER-negative 
cancers.  The International Breast Cancer Intervention Study (IBIS-I)81 also found a significant 
reduction with tamoxifen compared to placebo with a 32% lower overall risk with tamoxifen.  
Similarly to BCPT, findings from IBIS-I showed a reduction for ER-positive invasive breast 
cancers (31%) but no effect for ER-negative invasive cancers.  The remaining two trials, the 
Italian Tamoxifen Prevention Study82,83 and the Royal Marsden Hospital trial84, did not find a 
statistically significant reduction in breast cancer with tamoxifen use, but both of the studies’ 
results trended toward a lower risk in the tamoxifen arm.  Differing study populations and 
designs may have contributed to the insignificant results; however, after combining data from all 
four trials, a significant reduction of 38% in breast incidence was seen with tamoxifen use85,86.  
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Furthermore, long-term follow-up (median time of 13 years) of the RMH study showed a highly 
significant reduction in ER-positive breast cancer with tamoxifen84.   
Based primarily on the results of BCPT, tamoxifen received approval from the United 
States Food and Drug Administration (FDA) for the risk reduction of invasive breast cancer 
among women aged 35 years and older who are at high risk for developing the disease.  
However, the drug was not without side effects.  Secondary endpoints of BCPT included 
evaluating the effect of tamoxifen on the risk of endometrial cancer, heart disease, 
thromboembolic events, cataracts, osteoporotic fractures (hip, spine and Colles), and several 
others in order to obtain a thorough risk/benefit analysis.  Although tamoxifen did not increase 
the risk for heart disease and trended toward a lower incidence of osteoporotic fractures (this 
relationship will be discussed further in section 2.3.2), it significantly increased the risk for 
endometrial cancer, thromboembolic events, and cataracts80.  Therefore, older women at high 
risk for endometrial cancer or vascular-related events are likely not good candidates for 
tamoxifen therapy.  Updated results from BCPT after seven years of follow-up were consistent 
with the original findings in relation to breast cancer and side effects87.  The updated data 
confirmed the reduction in risk of invasive breast cancer with tamoxifen therapy, and showed 
that the benefit remained for at least two years after women received tamoxifen. 
 Although tamoxifen was found to be beneficial for many women at high risk for 
developing breast cancer, the search continued for a therapy with an improved profile of side 
effects.  In 1999, results were released from the Multiple Outcomes of Raloxifene (MORE) trial, 
which was a randomized, placebo controlled trial designed to test whether raloxifene reduces the 
risk of fracture among postmenopausal women88,89.  A secondary endpoint of the trial was breast 
cancer for which they found a 72% reduction in invasive breast cancer with raloxifene compared 
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to placebo after four years of follow-up.  Based on these promising findings, three trials were 
launched to investigate the possible preventive effect of raloxifene on invasive breast cancer.  
The Continuing Outcomes Relevant to Evista (CORE) trial90 added four additional years of 
raloxifene therapy to women from MORE who agreed to participate.  They found that after 
approximately 8 years of therapy, raloxifene reduced the risk of invasive breast cancer by 66% 
compared to placebo.  They also found that the increase in thromboembolic events with 
raloxifene use was insignificant and that there was no increased risk for endometrial cancer.  The 
Raloxifene Use for The Heart (RUTH) trial91,92 was a double-blind, placebo-controlled, 
randomized trial designed to determine whether raloxifene reduced the risk of coronary events 
and invasive breast cancer in postmenopausal women at risk for a major coronary event.  Results 
showed a 44% reduction in total invasive breast cancers and a 55% reduction in risk of ER-
positive invasive breast cancer with raloxifene compared to placebo.  They found no effect on 
ER-negative breast cancers. 
The NSABP’s second breast cancer prevention trial, STAR93, was designed to determine 
the relative efficacy of raloxifene versus tamoxifen in the prevention of invasive breast cancer 
among postmenopausal women at high risk for developing breast cancer.  It was the only one of 
the randomized clinical trials involving raloxifene that compared it directly to tamoxifen instead 
of a placebo.  After four years of follow-up, STAR data showed that raloxifene was as effective 
as tamoxifen in preventing invasive breast cancer (RR 1.02, 95% CI 0.82-1.28).  Raloxifene also 
had a lower risk of endometrial cancer and a significantly lower risk of thromboembolic events 
and cataracts.  Although not significant, raloxifene did not perform as well as tamoxifen in 
preventing noninvasive breast cancer.  The combined results demonstrated that raloxifene 
provided an alternative to tamoxifen in preventing invasive breast cancer among postmenopausal 
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women at high risk for developing breast cancer, and FDA approval of raloxifene for this 
indication followed.  A recently released update of the STAR trial94 showed that after a median 
of 81 months (60 months of treatment and 21 months of follow-up) raloxifene retained 
approximately 76% of the effectiveness of tamoxifen representing a 38% reduction when 
compared to an untreated group.  The results also showed that the difference between tamoxifen 
and raloxifene in preventing noninvasive breast cancer narrowed and that raloxifene remained 
less toxic than tamoxifen.  The authors recommended that postmenopausal women with an intact 
uterus and an increased risk for breast cancer, osteoporosis, and fracture may be good candidates 
for raloxifene and that continuing raloxifene therapy after five years might be beneficial.  
 Despite the success of tamoxifen and raloxifene in breast cancer prevention clinical trials 
and the FDA approval of the drugs, few women are estimated to be actually taking the drugs for 
chemoprevention.  Disparities in access to treatment facilities and insurance coverage among 
racial/ethnic minority groups, low socioeconomic groups, and those in remote geographic areas 
of residence may be contributing to the underuse of chemoprevention95.  Several studies have 
been conducted to identify other reasons for the underuse of these chemopreventive drugs.  One 
study used an individually tailored decision aid to adequately inform women about their 
increased breast cancer risk based on the Gail score, and the benefits and risks of tamoxifen 
therapy96.  They found that even though high risk women in their study understood that 
tamoxifen would lower their breast cancer risk, they still had no interest in taking the drug and 
this reluctance was mostly due to concerns about side effects and beliefs that the risks would 
outweigh the benefits.  Another recent study97 reported that in the 10 years since the BCPT trial, 
the prevalence of tamoxifen use for chemoprevention in the United States was well below 1%.  
They indicated that in addition to patient concerns about side effects, part of the explanation 
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could be due to physician reluctance.  Neither primary care physicians nor oncologists have 
accepted the responsibility of assessing risk, providing counseling, and prescribing therapies for 
breast cancer chemoprevention98.  In a recent report99, Ravdin examined the number of filled 
prescriptions for tamoxifen and raloxifene from 1995 to 2008 and found concerning results.  In 
the two years following FDA approval for tamoxifen, its use for chemoprevention only slightly 
increased and has since declined in more recent years.  At the time of FDA approval of 
raloxifene in 2007, prescriptions for the drug in the United States were already declining and 
have continued to do so at the same rate.  Physician education regarding risk reduction options 
and internet-based decision-making tools may be beneficial and should be investigated in future 
research97,99.  Currently an exploratory, descriptive study (Decision Making for Prevention, 
DMP-1) is being conducted by the NSABP to gain a better understanding of the social and 
psychological factors involved in decisions about SERMs and breast cancer risk reduction so that 
tools to facilitate decision-making can be provided.   
In 2010, results were released regarding lasofoxifene, which is a third-generation SERM 
found to be effective in reducing the risk of breast cancer and fractures among postmenopausal 
women at risk for osteoporosis100.  The results showed a 79% decrease in breast cancer risk, a 
32% decrease in coronary events, and a 36% decrease in risk of stroke with 0.5 mg of 
lasofoxifene.  The study was limited with a small number of breast cancer events and further 
research is necessary, but researchers are hopeful that it could be an effective agent with a 
favorable risk/benefit profile that would be widely accepted by the public98.  Arzoxifene is 
another SERM that has been recently found to reduce the risk for breast cancer among 
postmenopausal women with osteoporosis or low bone mass.  There was a 56% reduction in 
breast cancer with arzoxifene compared to placebo, but similarly to other SERMs, arzoxifene 
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increased the risk of thromboembolic events and gynecologic adverse events101.  Other agents 
believed to have potential in breast cancer chemoprevention are aromatase inhibitors (i.e., 
anastrozole and exemestane) and retinoids (i.e., fenretinide)95.  Aromatase inhibitors have been 
successful in breast cancer treatment and are currently being compared to placebo for the 
prevention of ER-positive breast cancer among postmenopausal high risk women in two different 
clinical trials102,103.  Retinoids have been shown to reduce ER-negative breast cancer in animal 
models, making them ideal to use in combination therapy with SERMs to prevent both ER-
positive and ER-negative breast cancer95.  However, results of one study showed that the 
combination of low-dose tamoxifen and fenretinide did not reduce breast neoplastic events 
compared to placebo104.  Despite the possibilities for the future of chemoprevention, tamoxifen 
and raloxifene remain the only FDA approved chemopreventive agents recommended for use 
outside of the investigational setting. 
 
2.3.2 Association between Tamoxifen and Fracture Risk 
 
There are millions of women in the United States who are at risk for both breast cancer and 
osteoporosis98.  Osteoporosis is a skeletal disorder characterized by compromised bone strength 
predisposing to an increased risk of fracture.  Bone strength is a reflection of BMD which is 
determined by peak bone mass and amount of bone loss, and bone quality which refers to 
architecture, turnover, damage accumulation, and mineralization105.  As mentioned before, 
tamoxifen has estrogen-agonist effects on the bone.  Consequently, the relationship between 
tamoxifen and BMD has been extensively studied in the literature, particularly in the adjuvant 
setting.  A review of 27 peer-reviewed articles focusing on the relationship between tamoxifen 
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and BMD concluded that tamoxifen increased BMD by approximately 2-4% in the hip and spine, 
but did not affect the wrist106.  Although tamoxifen has been shown to prevent bone loss in 
postmenopausal women, studies have found significant bone loss in patients who have remained 
premenopausal following tamoxifen therapy for breast cancer107-109.  The exact mechanisms for 
the different effects of tamoxifen by menopausal status remain unclear; however, it is believed to 
relate to the differing levels of endogenous estrogen before and after menopause.  In their 1996 
study of BMD in pre- and postmenopausal women, Powles et al. suggested that the effect of 
tamoxifen on the bone might be mediated by estrogen receptors in osteoblasts.  Thus the high 
premenopausal levels of estrogen may be modifying the sensitivity of the receptors causing 
tamoxifen to have an antagonist effect before menopause compared to an agonist effect after 
menopause107.     
Since BMD is a surrogate for osteoporotic fractures, one would also expect a decrease in 
fractures with tamoxifen use among postmenopausal women.  However, this relationship has not 
been studied as extensively, since using fractures as an endpoint requires longer follow-up time 
and larger sample sizes than studies of BMD.  A case-control study by Cooke et al.110 found a 
significant association between fewer fractures and current tamoxifen use (OR 0.69, 95% CI 0.54 
– 0.88); however, they did not find an association when considering tamoxifen use in the remote 
or recent past.  BCPT, which compared tamoxifen to placebo, looked at the effect of tamoxifen 
on fracture risk as a secondary endpoint80.  Results indicated that tamoxifen significantly lowered 
the risk for osteoporotic fractures of the hip, spine and radius (Colles) after seven years of 
follow-up (RR 0.68, 95% CI 0.51 – 0.92)87.  This represented five years of treatment followed by 
two years of additional follow-up, implying that protection persisted even after stopping therapy.  
Furthermore, evidence from the STAR trial indicated that there was no difference in the number 
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of fractures between those taking tamoxifen or raloxifene93,94.  The primary indication for 
raloxifene is osteoporosis prevention and raloxifene is known to reduce vertebral fractures 
among postmenopausal women111-113.  Therefore, the results of the STAR trial provide further 
evidence supporting a reduction in osteoporotic fractures with tamoxifen use.  However, more 
research is needed to determine whether this benefit exists for all women and extends to all 
fractures in addition to hip, spine, and Colles fractures.       
 
 
2.4 SUMMARY 
 
Lifestyle modifications may be helpful in lowering breast cancer risk.  For example, high body 
weight is believed to be associated with an increased risk for developing the disease, even though 
the biological explanations for this relationship are unclear.  Therefore, maintaining a healthy 
lifestyle by following a balanced diet, exercising, and reducing alcohol intake is recommended to 
reduce breast cancer risk and provide substantial overall health benefits.  However, we are 
uncertain whether the breast cancer benefit exists for all subtypes of breast cancer and among 
different subgroups of women.  Therefore, gaining a better understanding of the true effect that 
body weight has on breast cancer development among different populations can provide 
important insight into the prevention of the disease for many women.    
Other factors for increased breast cancer risk such as family history and those related to 
endogenous estrogen exposure (e.g., age at menarche, age at first live birth) are not easily 
modifiable.  Chemoprevention, which is the use of drugs to reduce the risk of disease, has been 
successful among these high-risk women.  Two drugs, tamoxifen and raloxifene, have been 
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found to reduce the risk of breast cancer among high risk women by 50% and 38% 
respectively80,94, and both have been approved by the FDA for breast cancer prevention.  
However, they are not without risks of side effects and toxicities.  Therefore, it is important to 
accurately predict who is at high risk for developing breast cancer and would benefit from 
preventive therapy.  The Gail model is the most widely used and tested method for doing just 
that; however, improvement to its predictive capability by exploring the addition of risk factors 
such as mammographic breast density remains of great interest.   
 Despite the availability of tamoxifen and raloxifene as chemopreventive agents, few 
women in clinical practice who carry an increased risk for developing breast cancer are willing 
to use them.  The majority of this reluctance is likely due to concerns and fear about side effects 
and believing that the risks outweigh the benefits of the drugs96.  Although some concern is 
warranted and each woman’s eligibility should be thoroughly evaluated by her physician through 
a risk-benefit analysis64, the unwillingness of many women may be impeding the preventive 
power of these drugs.  Understanding and providing more researched-based knowledge regarding 
some of the concerns surrounding breast cancer chemoprevention and highlighting concomitant 
benefits from the drugs may help to refine this area of research. 
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3.0 SPECIFIC AIMS 
 
Research Article 1 used data from the NSABP STAR and BCPT (P-1) randomized clinical trials 
to explore whether BMI at baseline was associated with the risk for invasive breast cancer.  This 
association was first explored among the STAR population, which consisted of women who were 
postmenopausal at the time of study entry, and subsequently among the postmenopausal women 
who participated in P-1.  Since P-1 also contained a group of women who were premenopausal at 
study entry, the relationship was explored among this population as well to determine whether 
the effect of BMI differed by menopausal status.  We tested for important explanatory variables 
including treatment group, Gail score, age, history of estrogen use, history of oral contraceptive 
use, history of diabetes, and years of cigarette smoking at entry.  We also explored whether the 
relationship between BMI and breast cancer risk differed among women who were treated with 
chemopreventive therapies and those who were not treated. 
 Research Article 2 investigated whether mammographic breast density based on the BI-
RADS classifications at baseline was associated with the risk of invasive breast cancer among 
STAR participants, and whether mammographic breast density improved the predictive 
capability of the Gail model.  We adjusted for possible explanatory variables including age, 
treatment group, BMI, years of cigarette smoking, and history of diabetes at entry.  We also 
investigated whether adding mammographic breast density to an abbreviated model improved 
the model’s ability to predict the risk of ER-positive breast cancer.  
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 Research Article 3 explored whether tamoxifen use lowered the risk of osteoporotic and 
all clinical fractures among participants of BCPT (P-1) at high risk for breast cancer, and if the 
effect of tamoxifen on fractures was consistent across subgroups of the population defined by the 
presence or absence of fracture risk factors.  The subgroups were defined by age, Gail score, 
BMI, menopausal status, smoking status, alcohol use, leisure time physical activity, history of 
diabetes, history of bone fracture, history of osteoporosis, prior use of estrogen, prior use of oral 
contraceptive, use of thyroid replacement medication, use of cholesterol lowering agents, use of 
calcium supplements, and a summary fracture risk score. 
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4.1 ABSTRACT 
 
High body mass index (BMI) has been associated with an increased risk for breast cancer among 
postmenopausal women.  However, the relationship between BMI and breast cancer risk in 
premenopausal women has remained unclear.  Data from two large prevention trials conducted 
by the National Surgical Adjuvant Breast and Bowel Project (NSABP) were used to explore the 
relationship between baseline BMI and breast cancer risk.  The analyses included 12,243 
participants with 253 invasive breast cancer events from the Breast Cancer Prevention Trial (P-1) 
and 19,488 participants with 557 events from the Study of Tamoxifen and Raloxifene (STAR).  
Both studies enrolled high-risk women (Gail score ≥ 1.66) with no breast cancer history.  
Women in P-1 were pre- and postmenopausal, while women in STAR (P-2) were all 
postmenopausal at entry.  Using Cox proportional hazards regression, we found slight but 
nonsignificant increased risks of invasive breast cancer among overweight and obese 
postmenopausal participants in STAR and P-1.  Among premenopausal participants, an increased 
risk of invasive breast cancer was significantly associated with higher BMI (P=0.01).  Compared 
to BMI<25, adjusted hazard ratios for premenopausal women were 1.59 for BMI 25–29.9 and 
1.70 for BMI≥30.  Our investigation among annually screened, high-risk participants in 
randomized, breast cancer chemoprevention trials showed that higher levels of BMI were 
significantly associated with increased breast cancer risk in premenopausal women older than 
age 35, but not postmenopausal women.  
  39 
4.2 INTRODUCTION 
 
Despite efforts to promote healthy lifestyle choices and to raise awareness about the 
consequences of excess body weight, overweight and obesity remain important public health 
challenges in the United States.  An alarming two-thirds of Americans are overweight or obese, 
and more than one-third is obese114.  Excess weight has been linked to an array of medical 
problems including cardiovascular disease, type 2 diabetes, osteoarthritis, and various types of 
cancer31,114.  Since body weight is a modifiable factor, understanding its relationship with breast 
cancer risk among women could provide helpful insight into the prevention of breast cancer.   
In epidemiologic studies, body mass index (BMI) is often the standardized method used 
for classifying excess weight.  BMI is calculated as weight in kilograms divided by height in 
meters squared.  There is extensive evidence in the literature supporting a relationship between 
increased BMI and an increased risk for breast cancer among postmenopausal women33-35,40.  
However, studies among premenopausal women are sparse and inconsistent.  Based on these 
limited results, some studies have suggested that obesity is protective among premenopausal 
women36,38-40, while others have found no association35,41,43.   
The most widely accepted explanation for the BMI and breast cancer risk association 
among pre- and postmenopausal women is related to estrogen production.  In premenopausal 
women, the ovaries are the primary source of estrogen in the body.  After menopause, most 
circulating estrogen derives from the conversion of adrenal androgens by means of adipose 
aromatase.  Therefore, women with higher amounts of body fat have higher levels of circulating 
estrogen.  Studies have found a stronger relationship between obesity and estrogen receptor 
(ER)-positive breast cancers than between obesity and ER-negative cancers45.  They have also 
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shown that a history of using postmenopausal hormone therapy (PHT) attenuates the relationship 
between obesity and breast cancer risk among postmenopausal women34.  Both of these findings 
provide further evidence for the estrogen availability theory among postmenopausal women.  
Other biologically plausible explanations include insulin resistance, obesity-induced 
inflammation, and expression patterns of proteins in mammary epithelial cells115,116. 
Despite the above explanations, we do not yet know the exact biological mechanisms for 
the development of breast cancer in obese women.  Due to this uncertainty, the proposed theories 
are laced with speculation43.  Inconsistent results, combined with speculative explanations, 
underscore the need for more research to clarify the relationship between BMI and breast cancer 
risk with respect to menopausal status among different populations of women.  In this report we 
use data from two large prospective chemoprevention trials [the Breast Cancer Prevention Trial 
(P-1) and the Study of Tamoxifen and Raloxifene (STAR, P-2)] conducted by the National 
Surgical Adjuvant Breast and Bowel Project (NSABP) to explore the relationship between BMI 
and invasive breast cancer in both pre- and postmenopausal women who are at high risk for 
developing breast cancer.  
 
 
4.3 METHODS 
 
4.3.1 Description of P-1 and STAR  
 
Both P-1 and STAR were two-arm, double-blinded, randomized clinical trials investigating the 
use of chemoprevention for breast cancer.  P-1 opened to accrual June 1, 1992.  One-hundred-
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thirty-one clinical centers throughout North America enrolled 13,388 women by September 30, 
1997.  Each woman was randomly assigned to receive either placebo or tamoxifen for five years.  
In March of 1998, the trial was stopped and unblinded as a result of sufficiently strong findings 
indicating a 49% reduction in breast cancer risk with tamoxifen use80.  A 2005 update of the 
results with seven years of follow-up showed that tamoxifen remained effective in reducing 
breast cancer risk for two years after stopping therapy87.   
The NSABP’s second breast cancer prevention trial, STAR, was designed to compare the 
relative effects of raloxifene to tamoxifen on breast cancer risk as well as other diseases found to 
be associated with tamoxifen in the P-1 trial.  Two hundred centers throughout North America 
enrolled and randomized 19,747 participants to STAR between July 1, 1999, and November 4, 
2004.  The trial results were reported in April 2006 and indicated that raloxifene was as effective 
as tamoxifen in preventing invasive breast cancer; however, the toxicity and side effect profiles 
favored raloxifene93.  A 2010 update of the findings indicated that raloxifene maintained 76% of 
the effectiveness of tamoxifen in preventing invasive breast cancer (i.e., raloxifene was 24% 
inferior to tamoxifen) and continued to remain less toxic94.  For both trials, all clinical centers 
obtained approval from institutional review boards, and all participants provided written 
informed consent.   
To be eligible for enrollment into P-1 or STAR, women had to be at least 35 years of age 
with no history of invasive breast cancer.  Women also had to be at high risk for developing 
breast cancer, which was defined as having a history of lobular carcinoma in situ, having a 
minimum projected 5-year probability of invasive breast cancer (based on the Gail model) of at 
least 1.66%62,63, or, in P-1 only, being age 60 or older.  There was no menopausal status 
exclusion criterion for P-1 participation, but STAR participants were required to be either 
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surgically or naturally postmenopausal.  Women were excluded from P-1 and STAR if they had 
previously undergone a bilateral or unilateral prophylactic mastectomy.  Women were also 
required to have discontinued all use of estrogen or progesterone replacement therapy, oral 
contraceptives, or androgens for at least three months before random assignment.  Other 
inclusion and exclusion criteria, including certain medications and conditions, along with further 
details regarding the scientific rationale and additional aspects of the design and recruitment of 
P-1 and STAR have been previously published80,93.   
 Participants were followed every six months for the first five years and annually 
thereafter.  In order to capture all diagnoses of invasive breast cancer, they received a physical 
breast examination at each six-month follow-up appointment and bilateral mammograms 
annually.  Staff members from the participating clinical centers were responsible for performing 
participant follow-up and were required to submit documentation for each event reported.  The 
documentation was reviewed centrally by trained medical professionals at the NSABP to confirm 
the diagnosis of each event.   
 
4.3.2 Study Design 
 
The current study included all participants of P-1 and STAR with follow-up information and 
known menopausal status and BMI at entry.  Because a large portion (almost 32%) of women 
assigned to placebo in P-1 crossed over to active treatment with tamoxifen at the time the 
findings were reported (March 31, 1998), follow-up data for all P-1 participants were censored at 
that time, representing an average of 4.1 years of follow-up.  Follow-up for the STAR population 
is based on the data used in the most recent update of the trial (March 31, 2009), representing an 
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average of 6.4 years of follow-up.  The flow of participants included in the current study is 
shown in Figures 1A and 1B.  For P-1 participants, menopausal status was inferred from 
questions about menstrual history at entry.  A woman was considered postmenopausal if she 
reported that both of her ovaries were removed or if she indicated that her menstrual periods had 
stopped for at least 12 months.  For those women with missing information or who underwent a 
hysterectomy before entry but had at least one intact ovary and were menstruating at the time of 
their hysterectomy, menopausal status was classified based on each woman’s age at entry.  
Women younger than age 50 were classified as premenopausal, and women aged 60 or older 
were considered postmenopausal.  For women aged 50-59, we could not confidently make any 
assumptions based on age; consequently, their menopausal status at entry was considered 
unknown and they were excluded from this evaluation.   
In both P-1 and STAR, each participant’s height and weight were measured and recorded 
by clinical staff members at each participating clinical center.  These measurements were used to 
calculate individual BMIs.  For adults, BMI is usually grouped into four categories of weight 
classification:  underweight (<18.5), normal (18.5 – 24.9), overweight (25.0 – 29.9), and obese 
(≥ 30.0).  Because of the low numbers of women falling into the underweight category in our 
population, it was combined with the normal group to form three categories of BMI for this 
analysis.  
Information about important explanatory variables was also collected at baseline.  As an 
eligibility assessment, participants were required to complete a risk assessment form that 
gathered information regarding current age, race, age at menarche, age at first live birth, number 
of previous breast biopsies, presence of atypical hyperplasia, and number of first-degree relatives 
with a history of breast cancer.  Using these responses, the 5-year predicted breast cancer risk 
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(Gail score) was centrally calculated by the NSABP Biostatistical Center.  Other variables, 
including history of estrogen use, history of oral contraceptive use, history of diabetes, and 
smoking history, were assessed via questionnaires that had been administered at the time the 
women entered the original studies. 
 
4.3.3 Statistical Analysis   
 
We used the STAR population to first explore the relationship between BMI and invasive breast 
cancer in postmenopausal women.  We then looked at postmenopausal women from P-1 to see if 
these results would be consistent.  Since P-1 also enrolled women before menopause, we were 
able to use this group to explore the relationship between BMI and invasive breast cancer in 
premenopausal women.  For each of the groups (i.e., STAR postmenopausal, P-1 
postmenopausal, and P-1 premenopausal), we used Cox proportional hazards regression to 
calculate unadjusted and adjusted hazard ratios of developing invasive breast cancer for 
overweight (BMI 25.0 – 29.9) and obese (BMI ≥ 30.0) participants compared to those of normal 
or low weight (BMI < 25.0).  Time to invasive breast cancer was calculated as time from 
randomization to diagnosis of invasive breast cancer or time of last follow-up.  Time was 
censored for those who had undergone a bilateral mastectomy or died during follow-up.  P 
values for tests for trend were obtained by including BMI as a single ordinal term (with values 0, 
1, and 2) in the models and evaluating the global P value for the term.  We first assessed the 
association between BMI and the risk of breast cancer on a univariable basis, and then we 
assessed the association utilizing two forms of adjustment for important explanatory variables.  
The first was achieved using Cox regression modeling that incorporated all key potential 
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variables including treatment, Gail score, age, history of diabetes, history of oral contraceptive 
use, history of estrogen use, and years of cigarette smoking at entry.  We refer to this as the full 
multivariable model assessment.  Because the majority of P-1 and STAR participants are white 
(94-97%) and race is incorporated into the Gail score, we did not include race/ethnicity as a 
potential factor.  As a second form of adjustment, we used backward elimination to drop out all 
of the potential variables that did not reach a statistically significant level of P<0.05.  We refer to 
this as the final multivariable model assessment.  Based on results reported in the literature, we 
tested for an interaction between BMI and history of estrogen use among postmenopausal 
women, and an interaction between BMI and history of oral contraceptive use among 
premenopausal women.  Since our populations consisted of women receiving chemopreventive 
therapy, we decided a priori to conduct analyses separately among treated and untreated women.  
To assess whether effects of BMI differed by receptor status of the tumor, we conducted separate 
analyses for ER-positive and ER-negative breast cancers among postmenopausal and 
premenopausal women.  For the analysis of ER-positive breast cancer, we censored the ER-
negative cancers and those with unknown ER status at the time of diagnosis.  Similar logic was 
followed when ER-negative breast cancer was the outcome of interest.  Assessments of the 
statistical significance of interactions and effects within treatment groups and by ER status were 
based on the final multivariable model for the respective study populations. P values used to 
assess the statistical significance of parameters in all modeling were determined using the 
likelihood ratio test.  All tests were evaluated using a 2-sided P = 0.05.  Analyses were 
performed using SAS version 9.2 software (SAS Institute, Inc). 
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4.4 RESULTS 
 
Entry characteristics for the three groups of participants included in this analysis (i.e., STAR 
postmenopausal, P-1 postmenopausal, and P-1 premenopausal) by BMI are included in the top 
portion of Table 1.  Among postmenopausal women in STAR and P-1, the mean ages were 58.5 
(SD, 7.4) and 60.8 (SD, 7.5) years, respectively.  Among the premenopausal women in P-1, the 
mean age was 46.3 (SD, 4.3) years.  STAR participants had higher Gail scores, with a mean 5-
year predicted breast cancer risk of 4.03% (SD, 2.2) compared to 3.87% (SD, 2.8) among 
postmenopausal women and 3.28% (SD, 2.0) among premenopausal women in P-1.  Overall, 
obese women were more likely to have a history of diabetes and less likely to have smoked or to 
have used oral contraceptives.  In addition, obese women tended to have slightly lower Gail 
scores than women of normal weight.  More overweight and obese premenopausal women 
reported a history of estrogen use, while obese postmenopausal women were less likely to have 
used estrogen.  The distributions of tumor characteristics of the cases by BMI are presented in 
the bottom portion of Table 1.  Obese women were slightly more likely to have ER-positive 
breast cancer than women of normal weight.  
The results of univariable and multivariable analyses of the association between BMI and 
the risk of developing invasive breast cancer are shown in Table 2 for postmenopausal women 
and Table 3 for premenopausal women.  Of all the potential explanatory variables assessed, only 
treatment, Gail score, and age were statistically significant in STAR; and only treatment and Gail 
score were statistically significant in P-1.  Among postmenopausal women in STAR, there was a 
slight but nonsignificant increased risk of invasive breast cancer with increasing levels of BMI 
(Table 2, first portion).  Adjusting for all potential explanatory variables (full multivariable 
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model assessment) or for only those that were statistically significant in the study population 
(final multivariable model assessment) had negligible effects on the point estimates of the hazard 
ratios or on the conclusions regarding the tests of trend. Compared to the lowest group (BMI 
<25.0), the hazard ratios for the two increasing BMI categories from the final multivariable 
model were 1.04 and 1.16, and the P value for the trend test was 0.16.  
When considering the results among P-1 postmenopausal women, the findings were 
similar to those seen in STAR in that there was no statistically significant trend of breast cancer 
risk across BMI categories (Table 2, second portion).  Again, adjustment for possible 
explanatory variables had little effect on the point estimates of the hazard ratios or the tests of 
trend.  The hazard ratios for the upper two categories of BMI from the final multivariable model 
were 1.22 and 1.09, and the P value for the test of trend was 0.68.  Since the results were 
consistent for postmenopausal women from both STAR and P-1, these two populations were 
combined to obtain more precise estimates of hazard ratios and confidence intervals (Table 2, 
last portion).  There were 710 participants on the placebo arm of P-1 who were also participants 
in STAR.  These women were only included once in this combined analysis, using the 
information obtained from their P-1 participation.  The hazard ratios across BMI categories from 
the final multivariable model for the combined population of postmenopausal women were 1.07 
and 1.14, and the P value for the test of trend was 0.17.   
The findings for premenopausal women were different than those found for 
postmenopausal women (Table 3).  For this population, all assessments indicated a statistically 
significant trend of increasing breast cancer risk with increasing categories of BMI.  As in the 
postmenopausal populations, adjustment for explanatory variables had very little effect on the 
hazard ratio estimates or the conclusions regarding the tests of trend.  When considering the final 
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multivariable model, the hazard ratios for the upper BMI categories were 1.59 and 1.70, and the 
test of trend was statistically significant (P=0.01).   
 There was no evidence of a significant interaction between BMI and history of estrogen 
use among STAR/P-1 postmenopausal women (P=0.93), or between BMI and history of oral 
contraceptive use among premenopausal women (P=0.66).  Results from analyses stratified by 
treatment group are shown in Table 4.  When considering the untreated (placebo) group of 
postmenopausal women, the hazard ratios for the overweight and obese groups were elevated 
(1.77 and 1.28, respectively), but did not show a statistically significant trend (P=0.36).  Among 
the treated (tamoxifen or raloxifene) groups of postmenopausal women, we found no association 
between BMI and invasive breast cancer.  For raloxifene users, hazard ratios for the two upper 
categories of BMI were 0.92 and 1.07 (P value for trend 0.61) and for tamoxifen users, hazard 
ratios were 1.07 and 1.18 (P value for trend 0.26).  A test of interaction between BMI category 
and treatment group (treated vs. untreated) among the postmenopausal women was not 
significant (P=0.09).   
 Among premenopausal women, there was also no evidence of an interaction between 
BMI and treatment group (P=0.59), although premenopausal obese women randomly assigned to 
tamoxifen had a greater risk of breast cancer than non-obese women.  Among those who 
received tamoxifen therapy, the hazard ratios were 1.79 and 2.33 for overweight and obese 
women, respectively (P value for trend 0.02).  In the placebo group, there was not a statistically 
significant association between the risk of breast cancer and BMI (P value for trend 0.17); but 
the hazard ratios for the upper two categories of BMI remained elevated (1.51 and 1.41, 
respectively).   
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 Table 5 shows the results for ER-positive and ER-negative breast cancers separately.  
Among postmenopausal women, there was a nonsignificant positive association between BMI 
and ER-positive breast cancer (hazard ratios of 1.14 and 1.23 for the overweight and obese 
groups, respectively; P value for trend 0.07) and no association between BMI and ER-negative 
breast cancer.  Among premenopausal women, there was a statistically significant trend for BMI 
and ER-positive breast cancer with hazard ratios for the two upper categories of BMI of 1.41 and 
1.78 (P value for trend 0.04).  For ER-negative breast cancers, the test of trend was not 
statistically significant; but the number of breast cancer events among premenopausal women in 
each BMI category by ER status was small.     
 
 
4.5 DISCUSSION 
 
Our results indicate a statistically significant positive association between the risk of invasive 
breast cancer and BMI among premenopausal women over age 35 who were already at high risk 
for developing breast cancer.  Among high risk postmenopausal women in STAR and P-1, we 
found a slightly increased risk of invasive breast cancer among overweight and obese women, 
but the association was not significant.    
Much concern has been previously raised about the association between estrogen-only 
and combined estrogen/progestin PHT and breast cancer risk.  An observational study from the 
Women’s Health Initiative (WHI) showed that PHT use, defined as an estrogen-containing pill or 
patch, attenuated the association between BMI and breast cancer risk among postmenopausal 
women34, which is consistent with findings from other studies35,40.  However, results from two 
  50 
WHI clinical trials that compared estrogen plus progestin4 and estrogen-only117 therapy to 
placebo did not find an interaction between BMI and PHT.  We did not have the ability to assess 
combined estrogen/progestin PHT in this study; but over half of the P-1 and STAR 
postmenopausal participants reported a history of estrogen use.  This history may help to explain 
the increase in hazard ratio but lack of significant P value for obese postmenopausal women 
randomized to placebo in our study.  However, consistent with results from the WHI clinical 
trials, we did not find a significant interaction between BMI and history of estrogen use among 
postmenopausal women in our study.   
Similarly to PHT, oral contraceptive use has been a concern among premenopausal 
women.  A pooled analysis by van den Brandt and colleagues40 found that the inverse association 
between BMI and breast cancer risk was attenuated among women who had ever used oral 
contraceptives.  However, we found no effect of a history of oral contraceptive use among the 
premenopausal women who participated in the P-1 trial.  Researchers have also recently gained 
interest in exploring possible links between type 2 diabetes and the obesity/breast cancer risk 
relationship49,50.  Our study had very small numbers of participants with a history of diabetes (3-
6%), and although we tested for significance of this variable in our multivariable model, we were 
unable to further explore the relationship.  
 Prior research has suggested that high BMI is more strongly related to ER-positive than 
to ER-negative breast cancer, particularly among postmenopausal women38,45,118,119.  We 
assessed whether the effects of BMI differed by receptor status of the tumor in both post- and 
premenopausal women.  We found that among postmenopausal women, although neither reached 
statistical significance, BMI was more strongly associated with ER-positive breast cancer than 
ER-negative breast cancer.  Among premenopausal women, elevated hazard ratios were seen for 
  51 
both subtypes but a significant trend was only found for ER-positive cancers.  These results are 
consistent and not surprising given that obesity is believed to raise levels of circulating estrogen 
thereby increasing the risk of ER-positive cancer.  Conversely, a recent study found a direct 
association between abdominal adiposity and ER-negative breast cancer only47.  Our findings for 
premenopausal women conflict with these results; however, it should be noted that the number of 
cases by ER status and BMI classifications for premenopausal women in our study were too 
small to conduct any meaningful evaluations.   
According to existing literature, high BMI has been associated with a significantly 
increased breast cancer risk in postmenopausal women33-35 and is believed to be protective in 
premenopausal women33,36-38.  There are some possible explanations for why our results are 
inconsistent with these findings.  One of the most striking differences is that most of the 
participants in our study were being treated with tamoxifen or raloxifene, which are selective 
estrogen receptor modulators (SERMs).  SERMs reduce the risk of breast cancer by inhibiting 
estrogen-like activity in the breast.  Because of this anti-estrogenic activity, it could be that the 
use of SERMs alters the biological pathway by which obesity leads to increased breast cancer 
risk.  Although the trend remained nonsignificant, the hazard ratios among postmenopausal 
women were higher for those taking placebo than for those taking SERMs.  The elevated hazard 
ratios in the placebo group likely concur with prior studies and with the estrogen availability 
theory.  The interaction between BMI and treatment with SERMs was not significant, so we 
cannot make any definitive conclusions regarding differences by treatment groups.  However, the 
results are suggestive of a possible treatment effect among postmenopausal women and perhaps 
warrant more investigation in future studies.  In premenopausal women, it is unlikely that 
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chemoprevention was the primary reason for our contradictory results since we saw hazard ratios 
greater than 1.0 for overweight and obese women in both the placebo and treated populations.   
Another important difference between the current study and those prior is that our 
population consisted of women with a high risk for developing breast cancer.  Studies have 
shown that having a family history of breast cancer attenuates the inverse association between 
obesity and premenopausal breast cancer40,45.  Thus, there may be some underlying difference in 
high risk women that influences the effect of BMI on breast cancer risk.  Additionally, most 
studies have either censored premenopausal women at the time of menopause or assigned 
menopausal status at the time of diagnosis of breast cancer.  We did not update menopausal 
status throughout our study, and thus premenopausal women at entry may have been 
postmenopausal by the time of diagnosis.  Another difference is the age of our premenopausal 
women.  A study by Peacock and colleagues found that the inverse effect of obesity on 
premenopausal breast cancer risk was present only among women age 35 and younger120.  It is 
believed that this is likely due to anovulatory cycles and the subsequent decrease in progesterone 
and estradiol levels121.  In P-1, all women were over age 35 and so may have already been 
experiencing anovulatory cycles thereby washing out the protective effect of obesity.  However, 
a study conducted among premenopausal participants of the Nurses’ Health Study II found that 
the inverse association between BMI and breast cancer risk was not explained by menstrual cycle 
characteristics, infertility due to ovulatory disorders, or probable polycystic ovary syndrome38.    
Finally, we cannot rule out detection bias in other studies.  It is more difficult to palpate 
lumps in obese women with larger breasts than in other women51.  Unless heavier women 
undergo regular mammographic screening, they may be more likely to have a delayed diagnosis 
compared to women of normal weight.  This delay could push the detection of breast cancer to 
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the postmenopausal stage of life instead of before menopause, causing the association to look 
stronger among postmenopausal women38.  Invasive breast cancer was the primary endpoint in 
STAR and P-1 and was therefore clearly defined and accurately documented.  Furthermore, all 
participants were required to undergo regular physical breast examinations and mammographic 
screenings, making the current study less likely to be influenced by detection bias.    
  There are several limitations affecting our study.  Although STAR and P-1 were large 
randomized clinical trials with more than 19,000 and 13,000 participants, respectively, the 
numbers of cases of breast cancer in each population were limited.  It would be advantageous to 
have even larger populations with more cases to adequately explore the relationship between 
BMI and breast cancer risk by menopausal status, treatment, and ER status.  Because most of our 
participants were treated with tamoxifen or raloxifene, another possible concern is a difference in 
treatment adherence according to BMI.  However, a prior investigation of the P-1 data found no 
association between BMI and adherence to SERMs122.  Another limitation may be that we did 
not require blood tests to verify menopausal status in P-1; therefore, we did not know definitively 
the menopausal status for everyone, and perimenopausal women could have been classified as 
premenopausal.  Because of this limitation, we excluded 964 (7.3%) P-1 participants for whom 
menopausal status could not be determined (i.e., 50-59 year olds with a prior hysterectomy).  
Since these women were not missing at random, we compared their BMI and Gail scores to those 
of the same age group from P-1.  The distribution of BMI shifted only slightly with medians of 
26.6 and 27.0 for those included and excluded, respectively.  Furthermore, the breast cancer risks 
in these two groups were no different with median Gail scores of 2.66 for those included and 
2.72 for those excluded from the analysis.  Therefore, it is not likely that the exclusion of these 
women impacted the results to a meaningful degree.   
  54 
Another potential criticism may be that we did not control for levels of physical activity, 
which is related to both obesity and breast cancer15,20.  Physical activity levels were not collected 
in STAR, but were collected in P-1.  A previous investigation by Land et al. using P-1 data found 
no association between physical activity and invasive breast cancer19.  Finally, although BMI≥30 
is a common measure of obesity and is satisfactory for clinical and epidemiological purposes32, it 
is unclear whether it is the most ideal marker of obesity for breast cancer prediction.  BMI is a 
measure of general obesity, which has been linked to increased levels of estrogen in 
postmenopausal women.  However, waist circumference and waist-to-hip ratio are better 
measures of central obesity, which is related to metabolic changes and insulin resistance47,123.  
Information about waist and hip circumference was not collected in STAR, but we were able to 
explore the relationship between these measurements and invasive breast cancer in P-1 and 
found no association in the pre- or postmenopausal populations (data not shown).  However, 
more studies with multiple anthropometric measurements are needed to determine which ones 
may be more accurate markers for breast cancer prediction.  Furthermore, we only had measures 
of BMI at study entry, which may or may not be a true estimate of long-term obesity.  Some 
studies have suggested that BMI at age 18 reflects long-term obesity and thus may be a better 
marker for breast cancer risk38,42.  Despite the potential limitations of using BMI as a marker for 
obesity, the measurements of height and weight used in STAR and P-1 may provide more 
accuracy than studies that rely on self-reported data.   
In our population of high-risk women participating in chemoprevention clinical trials, we 
found no significant association between breast cancer risk and overweight and obesity among 
postmenopausal women, and a significant positive association among premenopausal women age 
35 and older.  These results are inconsistent with previous findings reported in the literature, 
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suggesting that the BMI/breast cancer association may not be the same for all women.  To our 
knowledge, this is the first study to explore the relationship between BMI and invasive breast 
cancer incidence in a randomized clinical trial population of high risk women who are being 
routinely screened for breast cancer development.  Due to the selective population and the small 
number of premenopausal breast cancer cases, more studies are needed to clarify the relationship 
between BMI and menopausal status and the risk of invasive breast cancer.  However, our results 
suggest that overweight and obesity are not protective among premenopausal women in this 
population and that maintaining a healthy weight is likely beneficial for all women at high risk 
for developing breast cancer.    
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4.6 TABLES AND FIGURES 
 
 
Table 4-1. Participant characteristics at entry and tumor characteristics for women 
included in the analyses by BMI 
a Determined by the Gail model. 
Abbreviations: n/a – not applicable.     
 
STAR Postmenopausal 
(N=19,488) 
P-1 Postmenopausal 
(N=6,379) 
P-1 Premenopausal 
(N=5,864) 
Body Mass Index Body Mass Index Body Mass Index 
< 25.0 25.0–29.9 ≥ 30.0 < 25.0 25.0–29.9 ≥ 30.0 < 25.0 25.0–29.9 ≥ 30.0 
Participant Characteristic (%) 
Total number of participants 5870 6703 6915 2204 2188 1987 2596 1785 1483 
Age (years)          
     ≤ 49 9.4 7.7 10.0 7.6 7.2 9.4 81.7 77.8 78.9 
     50-59 51.0 48.9 49.8 31.1 29.5 31.1 17.6 21.6 20.6 
     ≥ 60 39.6 43.4 40.2 61.3 63.3 59.6 0.7 0.7 0.5 
Treatment          
    Placebo n/a n/a n/a 49.2 51.7 50.0 50.2 50.1 50.4 
    Tamoxifen 50.5 49.8 49.7 50.8 48.3 50.0 49.8 49.9 49.6 
    Raloxifene 49.5 50.2 50.3 n/a n/a n/a n/a n/a n/a 
5-year predicted breast cancer riska          
     ≤ 2.00 11.3 10.8 11.1 20.9 23.0 22.5 27.3 30.3 33.6 
     2.01-3.00 28.7 29.7 32.0 27.7 26.8 29.0 32.5 32.7 32.8 
     3.01-5.00 32.6 31.5 30.4 30.2 29.5 28.7 26.0 23.1 22.3 
     ≥ 5.01 27.4 28.1 26.4 21.2 20.7 19.8 14.1 13.9 11.3 
History of diabetes          
     No 98.2 95.7 89.2 98.0 95.5 89.9 98.6 97.7 94.1 
     Yes 1.8 4.3 10.8 2.0 4.5 10.1 1.4 2.3 5.9 
History of estrogen use          
     No 25.6 26.5 30.6 45.6 45.7 51.0 89.6 86.9 88.4 
     Yes 74.4 73.5 69.4 54.4 54.3 49.0 10.4 13.1 11.6 
History of oral contraceptive use          
     No 31.8 31.9 33.8 56.2 59.5 56.8 18.5 20.6 23.3 
     Yes 68.2 68.1 66.2 43.8 40.5 43.2 81.5 79.4 76.7 
History of smoking (years)          
     None 55.5 55.2 55.7 53.8 56.8 57.0 53.9 51.6 56.3 
     < 15 14.1 12.5 11.9 10.0 8.9 8.6 17.7 15.4 14.8 
     15-34 19.4 21.5 21.8 21.1 21.2 21.4 27.4 31.3 27.4 
     ≥ 35 10.3 10.1 9.9 14.7 12.9 12.6 0.8 1.5 1.3 
     Unknown 0.7 0.7 0.7 0.5 0.3 0.5 0.2 0.3 0.2 
Tumor Characteristic (%) 
Total number of cases 159 191 207 42 48 37 43 45 38 
Tumor size          
≤ 1.0 35.8 39.3 31.9 35.7 47.9 51.4 39.5 22.2 23.7 
1.1-3.0 56.0 49.7 54.6 47.6 47.9 45.9 41.9 62.2 60.5 
≥ 3.1 5.0 9.4 8.7 14.3 4.2 2.7 18.6 15.6 15.8 
Unknown 3.1 1.6 4.8 2.4 0 0 0 0 0 
Nodal status          
Negative 74.2 73.3 71.5 69.0 70.8 81.1 65.1 57.8 60.5 
Positive 21.4 21.5 24.6 23.8 22.9 13.5 32.6 37.8 31.6 
Unknown 4.4 5.2 3.9 7.1 6.3 5.4 2.3 4.4 7.9 
Estrogen receptor status          
Negative 25.8 25.1 23.2 21.4 16.7 21.6 25.6 40.0 26.3 
Positive 68.6 73.3 74.4 71.4 72.9 73.0 62.8 55.6 65.8 
Unknown 5.7 1.6 2.4 7.1 10.4 5.4 11.6 4.4 7.9 
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Table 4-2. BMI and incidence of invasive breast cancer among postmenopausal women 
  STAR Postmenopausal P-1 Postmenopausal STAR/P-1 Postmenopausala 
Form of Cox 
Regression 
Model 
BMI N 
No. of 
Events 
HR (95% CI) N 
No. of 
Events 
HR (95% CI) N 
No. of 
Events 
HR (95% CI) 
Univariable 
assessment 
< 25.0 5870 159 1.00 2204 42 1.00 7883 194 1.00 
25.0–29.9 6703 191 1.06 (0.86 – 1.30) 2188 48 1.21 (0.80 – 1.84) 8641 228 1.08 (0.89 – 1.30) 
≥ 30.0 6915 207 1.14 (0.93 – 1.40) 1987 37 1.07 (0.69 – 1.66) 8633 231 1.11 (0.92 – 1.34) 
Ptrend   0.22   0.74   0.29 
Full 
multivariable 
assessmentb 
< 25.0 5829 159 1.00 2194 42 1.00 7833 194 1.00 
25.0–29.9 6658 190 1.03 (0.83 – 1.27) 2182 48 1.23 (0.81 – 1.86) 8591 227 1.06 (0.87 – 1.28) 
≥ 30.0 6870 206 1.13 (0.92 – 1.40) 1978 36 1.07 (0.68 – 1.67) 8581 229 1.12 (0.92 – 1.36) 
Ptrend   0.24   0.73   0.25 
Final 
multivariable 
assessmentc 
< 25.0 5870 159 1.00 2204 42 1.00 7883 194 1.00 
25.0–29.9 6703 191 1.04 (0.85 – 1.29) 2188 48 1.22 (0.81 – 1.85) 8641 228 1.07 (0.88 – 1.30) 
≥ 30.0 6915 207 1.16 (0.94 – 1.42) 1987 37 1.09 (0.70 – 1.69) 8633 231 1.14 (0.94 – 1.38) 
Ptrend   0.16   0.68   0.17 
 
a For participants in both P-1 and STAR, only their P-1 data were included. 
b Adjusted for treatment, Gail score, age, history of diabetes, history of oral contraceptive use,  
  history of estrogen use, and years of cigarette smoking; STAR/P-1 combined also adjusted for  
  trial.  Those with unknown smoking status were excluded from analyses. 
c Adjusted for treatment, Gail score and age in STAR and STAR/P-1 combined; and treatment  
  and Gail score in P-1. 
Abbreviations: HR-hazard ratio, CI-confidence interval.  
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Table 4-3. BMI and incidence of invasive breast cancer among premenopausal women 
 
 
a Adjusted for treatment, Gail score, age, history of diabetes, history of oral contraceptive use, 
history of estrogen use, and years of cigarette smoking.  Those with unknown smoking status 
were excluded from analyses. 
b Adjusted for treatment and Gail score. 
Abbreviations: HR-hazard ratio, CI-confidence interval. 
  P-1 Premenopausal 
Form of Cox 
Regression Model 
BMI N 
No. of 
Events 
  HR (95% CI) 
Univariable 
assessment 
< 25.0 2596 43   1.00 
25.0–29.9 1785 45   1.57 (1.04 – 2.39) 
≥ 30.0 1483 38   1.63 (1.06 – 2.53) 
Ptrend     0.02 
Full multivariable 
assessmenta 
< 25.0 2590 43   1.00 
25.0–29.9 1780 45   1.55 (1.02 – 2.36) 
≥ 30.0 1480 38   1.66 (1.06 – 2.58) 
Ptrend     0.02 
Final multivariable 
assessmentb 
< 25.0 2596 43   1.00 
25.0–29.9 1785 45   1.59 (1.05 – 2.42) 
≥ 30.0 1483 38   1.70 (1.10 – 2.63) 
Ptrend     0.01 
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Table 4-4. BMI and incidence of invasive breast cancer by treatment group 
 BMI 
Raloxifene Tamoxifen Placebo 
N 
No. of 
Events 
HR (95% CI) N 
No. of 
Events 
HR (95% CI) N 
No. of 
Events 
HR (95% CI) 
STAR/P-1 
Postmenopausala 
< 25.0 2808 90 1.00 3990 81 1.00 1085 23 1.00 
25.0–29.9 3256 95 0.92 (0.69 – 1.22) 4254 95 1.07 (0.80 – 1.44) 1131 38 1.77 (1.05 – 2.97) 
≥ 30.0 3342 108 1.07 (0.81 – 1.42) 4298 100 1.18 (0.88 – 1.58)   993 23 1.28 (0.72 – 2.28) 
Ptrend   0.61   0.26   0.36 
P-1 
 Premenopausalb 
< 25.0 
 
1292 13 1.00 1304 30 1.00 
25.0–29.9   891 15 1.79 (0.85 – 3.76)   894 30 1.51 (0.91 – 2.50) 
≥ 30.0   736 15 2.33 (1.10 – 4.90)   747 23 1.41 (0.82 – 2.43) 
Ptrend   0.02   0.17 
 
a Adjusted for Gail score and age. 
b Adjusted for Gail score. 
Abbreviations: HR-hazard ratio, CI-confidence interval. 
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Table 4-5. BMI and incidence of ER-positive and ER-negative invasive breast cancer 
 BMI 
ER-Positive Cancer ER-Negative Cancer 
N 
No. of 
Events 
HR (95% CI) N 
No. of 
Events 
HR (95% CI) 
STAR/P-1 
Postmenopausala 
< 25.0 7883 134 1.00 7883 48 1.00 
25.0–29.9 8641 167 1.14 (0.91 – 1.43) 8641 53 1.00 (0.68 – 1.48) 
≥ 30.0 8633 171 1.23 (0.98 – 1.55) 8633 53 1.03 (0.70 – 1.52) 
Ptrend   0.07   0.88 
P-1 
Premenopausalb 
< 25.0 2596 27 1.00 2596 11 1.00 
25.0–29.9 1785 25 1.41 (0.82 – 2.43) 1785 18 2.52 (1.19 – 5.33) 
≥ 30.0 1483 25 1.78 (1.03 – 3.07) 1483 10 1.79 (0.76 – 4.22) 
Ptrend   0.04   0.12 
 
a Adjusted for treatment, Gail score and age. 
b Adjusted for treatment and Gail score. 
Abbreviations: ER-estrogen receptor, HR-hazard ratio, CI-confidence interval. 
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Figure 4-1. CONSORT diagrams of P-1 (A) and STAR (B) 
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5.1 ABSTRACT 
 
Mammographic breast density is an established risk factor for breast cancer.  However, results 
are inconclusive regarding its use in risk prediction models.  The current study evaluated 13,409 
postmenopausal participants of the NSABP Study of Tamoxifen and Raloxifene.  A measure of 
breast density as reported on the entry mammogram report was extracted and categorized 
according to The American College of Radiology Breast Imaging Reporting and Data System 
(BI-RADS) classifications.  An increased risk of invasive breast cancer was associated with 
higher mammographic breast density (P=0.001).  The association remained significant after 
adjusting for age, treatment, and smoking history (HR 1.32, 95%CI 1.16–1.58), as well as when 
added to a model including the Gail score (HR 1.33, 95%CI 1.14–1.55).  At five years after 
random assignment, time-dependent AUC improved from 0.63 for a model with Gail score alone 
to 0.64 when considering breast density and Gail score.  Breast density was also significant when 
added to an abbreviated model tailored for estrogen receptor positive breast cancers (P=0.02).  In 
this study, high BI-RADS breast density was significantly associated with increased breast 
cancer risk when considered in conjunction with Gail score, but provided only slight 
improvement to the Gail score for predicting the incidence of invasive breast cancer.  The BI-
RADS classification system is a quick and readily available method for assessing breast density 
for risk prediction evaluations; however, its addition to the Gail model does not appear to 
provide substantial predictability improvements in this population of postmenopausal healthy 
women at increased risk for breast cancer. 
 
  
  64 
5.2 INTRODUCTION 
 
Breast cancer is the most frequently diagnosed cancer among women worldwide5.  Therefore, 
accurately identifying women who have an increased risk for developing breast cancer so they 
may be targeted for increased screening or preventive interventions remains a high priority.  The 
primary method for assessing non-genetic breast cancer risk is currently based on the Gail 
model62,63,68-70,73.  It is a validated statistical model that has been widely accepted for breast 
cancer prediction.  The Gail model does not currently include a measure of breast density, which 
has been associated with a three- to five-fold increased risk of breast cancer for women with 
dense tissue occupying more than half of their breast28-30.  Some studies have suggested that 
adding a measure of breast density to the Gail model may improve its predictive capabilities29,77-
79; however, it is not clear whether this is true in all populations or if the gain in predictability is 
of sufficient magnitude to warrant the addition of breast density to the model.   
Breast density is most commonly measured through mammography.  On a mammogram, 
fat appears dark since it is radiologically lucent; but connective and epithelial tissue are 
radiologically dense.  Thus, mammographic breast density is a measure of the area of the breast 
that appears white on a mammogram.  There are various methods for classifying mammographic 
breast density.  Due to convenience and cost, the most widely used is based on The American 
College of Radiology Breast Imaging Reporting and Data System (BI-RADS)54.  This method 
instructs radiologists to include a qualitative classification of breast density in each mammogram 
report they generate.  The classification system has four categories:  almost entirely fat (<25% 
glandular), scattered fibroglandular densities (25-50% glandular), heterogeneously dense (51-
75% glandular), or extremely dense (>75% glandular).  The BI-RADS classifications have been 
  65 
found to have only moderate inter-observer agreement.  However, these guidelines are routinely 
followed in clinical practice in the United States for reporting mammographic breast density, 
making them readily available for possible use in risk prediction tools55,61.   
The Gail model predicts a woman’s five-year and lifetime risk for developing breast 
cancer based on her reproductive, medical, and family history.  The individual risk factors that 
are currently included in the model are age at assessment, race, the number of previous breast 
biopsies, history of atypical hyperplasia in the breast, age of menarche, parity, age at the first live 
birth of a child, and history of breast cancer in a first degree female relative (i.e., mother, sister, 
daughter).  Any woman with a five-year risk of invasive breast cancer of 1.66% or greater is 
considered to be at high risk and should be evaluated further.  Although some simple lifestyle 
modifications can help to reduce risk, other more complex prophylactic techniques may be 
considered.  One's risk for breast cancer can be reduced by bilateral mastectomy (90%), or 
chemopreventive therapies such as tamoxifen or raloxifene (50%).  However, these interventions 
are not without risk for other complications or side effects80,93,124.  The Gail model has good 
calibration which indicates accuracy in predicting incidence of breast cancer in subgroups of 
women.  However, as is common with most risk prediction models for relatively rare diseases74, 
the Gail model has low discrimination (c-statistics ranging from 0.58–0.62) and therefore only 
modestly distinguishes at the individual level who will and will not develop breast cancer.  
Researchers have suggested that different risk prediction models might perform better for 
different subgroups of women (i.e., premenopausal vs. postmenopausal) or for different types of 
breast cancer (i.e., estrogen receptor [ER]-positive vs. ER-negative)75.  Using data from the 
Women’s Health Initiative (WHI), Chlebowski and colleagues attempted to find improved risk 
prediction models when considering ER-status among postmenopausal women75,76.  They 
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determined that adding additional risk factors to the Gail model did not provide significant 
improvement.  However, they also found that for ER-positive breast cancer in postmenopausal 
women, a more parsimonious model performed nearly as well as the Gail model with similar 
discriminatory accuracy.  The simpler model included age, family history of breast cancer, and a 
history of a previous breast biopsy.  Chlebowski and colleagues assessed a number of personal 
characteristics but did not have the ability to assess breast density.  Improving risk prediction 
models by including mammographic breast density has been supported in existing literature29,77-
79; however, this needs to be studied in multiple independent populations before being put into 
clinical use. 
In this report, we used data collected through the National Surgical Adjuvant Breast and 
Bowel Project (NSABP) Study of Tamoxifen and Raloxifene (STAR) to investigate the 
relationship between baseline mammographic breast density and the risk of invasive breast 
cancer.  STAR was a randomized clinical trial that compared the relative effects of raloxifene to 
tamoxifen on breast cancer risk.  We used data from this large breast cancer prevention trial to 
investigate whether a routine assessment of mammographic breast density improves the 
predictability of the Gail model and helps to more accurately identify women who might benefit 
from preventive therapies. 
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5.3 METHODS 
 
5.3.1 Description of STAR  
 
Between July 1, 1999 and November 4, 2004, a total of 19,747 participants at nearly 200 clinical 
centers throughout North America were enrolled and randomly assigned to receive either 
tamoxifen or raloxifene.  Each clinical center obtained approval from institutional review boards, 
and all participants provided written informed consent.  In April 2006, initial trial results showed 
that raloxifene was as effective as tamoxifen in preventing invasive breast cancer and was less 
toxic93.  An update of the findings in 2010 indicated that raloxifene continued to have fewer side 
effects, and maintained 76% of the effectiveness of tamoxifen in preventing invasive breast 
cancer94.   
 STAR participants were postmenopausal with no prior history of invasive breast cancer.  
Upon entry, each participant was assessed for all risk factors included in the Gail model, and 
only those considered to be at high risk for developing breast cancer, defined by a Gail score 
≥1.66% or having a history of lobular carcinoma in situ, were eligible for the study.  Participants 
were also required to have a baseline mammogram indicating absence of disease, and were 
required to submit documentation of this mammogram to the NSABP Biostatistical Center.  
Women were excluded from STAR if they had a prior bilateral or unilateral prophylactic 
mastectomy, a prior history of invasive breast cancer, or invasive cancer of any other type less 
than five years before random assignment with the exception of basal or squamous cell 
carcinoma of the skin.  Other inclusion and exclusion criteria, along with additional details 
regarding the design and recruitment of STAR have been previously published93.   
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 Follow-up for STAR participants occurred every six months for the first five years of the 
study and annually thereafter.  Each participant received an annual bilateral mammogram and a 
physical breast examination at each follow-up appointment.  Participants were also assessed at 
each follow-up visit for information regarding all other events of interest including the diagnosis 
of other invasive cancers, cardiovascular disease, thromboembolic disease, and fractures.  Staff 
members at each clinical center collected documentation for all reported events and submitted 
the documentation to the NSABP.  Diagnosis of each event was then centrally reviewed and 
confirmed by trained medical professionals.   
 
5.3.2 Study Design 
  
The current study included all STAR participants with follow-up for whom breast density 
information could be abstracted from the baseline mammogram report.  Follow-up was based on 
data used in the most recent update of the trial (March 31, 2009), representing an average of 6.3 
years.  The flow of participants included in the current study is shown in Figure 1.  Three women 
were excluded from the analyses because they were not at risk for invasive breast cancer due to a 
previous bilateral mastectomy or diagnosis of breast cancer.    
We used the entry mammogram reports to determine each woman’s BI-RADS category 
of breast density.  Of the 19,490 eligible STAR participants with follow-up data, entry 
mammogram reports were reviewed for 18,544 women (95%).  We did not include women with 
non-English mammogram reports (mostly from French-Canadian clinical sites), as well as those 
for whom we did not have an entry mammogram report available.  An independent reviewer 
trained in radiology examined each available mammogram report and completed a breast density 
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form based on the reported findings.  Specifically, the reviewer searched each report for a 
qualitative description and/or a quantitative percentage of breast density.  At least one measure 
of breast density was described in the report for 13,409 participants, with most reporting only a 
qualitative description (99%).  There were four mammogram reports that contained only percent 
breast density, and these were categorized into one of the four BI-RADS groups based on the 
coinciding recommended percentage ranges by the American College of Radiology.  There were 
also 100 reports that included both measures, and of those, 93 contained a percent breast density 
that agreed with those recommended in the BI-RADS classifications.  For the remaining seven 
that did not agree, the breast density category was assigned based on the percent density 
information since it has been shown to be more accurate than the qualitative categories55,125.   
The Gail scores were centrally calculated at the NSABP Biostatistical Center using 
information about all risk factors included in the Gail model collected from participants during 
eligibility assessments for STAR.  Each participant’s height and weight were measured at entry 
by clinical staff members at each participating clinical center and these measurements were used 
to calculate body mass index (BMI).  Other variables, including smoking history and history of 
diabetes were assessed via questionnaires that had been administered upon entry. 
 
5.3.3 Statistical Analysis   
 
We used the chi-square test to compare the distributions of participant characteristics at entry 
according to BI-RADS categories of breast density.  Cox proportional hazards regression was 
used to determine whether mammographic breast density at entry was associated with invasive 
breast cancer.  Breast density was first explored as a 4-class variable, but based on the 
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appearance of an approximately linear increase in the hazards of invasive breast cancer; we 
decided to include breast density as a single ordinal term (with values 0, 1, 2, and 3 representing 
the four BI-RADS categories) in the model.  We adjusted for possible explanatory variables 
including age, treatment group, BMI, years of cigarette smoking, and history of diabetes upon 
entry by including them in the model with breast density.  The majority of the participants were 
white (93%) and there were only 19 cases of breast cancer diagnosed among non-white 
participants, so we did not include race/ethnicity as a potential factor.  We used backward 
elimination to drop out all of the potential variables that did not reach a statistically significant 
level of P<0.05.  Because treatment with tamoxifen or raloxifene may differentially affect breast 
density, we tested for an interaction between breast density and treatment.  We then added breast 
density to a model with the Gail score and subsequently to a model including Gail score and the 
significant explanatory variables.  We calculated the time to invasive breast cancer as the time 
from random assignment to the date of diagnosis of invasive breast cancer.   If the participant did 
not experience invasive breast cancer, her time was censored on the first of three possible 
occurrences including bilateral mastectomy, date of death, or date of last follow-up.   
A secondary analysis investigated an abbreviated model developed by Chlebowski and 
colleagues75 that was tailored for ER-positive breast cancer.  Chlebowski’s abbreviated model 
included only age, number of first-degree relatives with breast cancer, and number of previous 
breast biopsies.  Our measure of breast density was added to this model to determine whether it 
significantly improved the predictability for this specific type of breast cancer.  The variables for 
number or relatives and biopsies were coded in the same way that was reported by Chlebowski et 
al. (0 or ≥1 for number of relatives and 0, 1, or >1 for number of biopsies) and time to diagnosis 
was censored for ER-negative invasive breast cancers and those for whom ER status was 
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unknown.  P values used to assess the statistical significance of variables in all modeling were 
determined using the likelihood ratio test, and all tests were evaluated using a 2-sided P value of 
0.05.  Analyses were performed using SAS version 9.2 software (SAS Institute, Inc).   
We assessed the discriminatory accuracy of the models through the use of time-
dependent receiver operator characteristic (ROC) curves and the corresponding area under the 
curve (AUC)126.  ROC curves plot the true-positive rate (sensitivity) versus the false-positive rate 
(1-specificity) for all possible threshold values for the probability of an outcome at a specific 
time, t.  The corresponding AUC(t) represents the probability that a person with onset of disease 
by time t has a higher risk score than a person with no event by time t.  An ROC curve 
representing a non-predictive model would connect the coordinates (0,0) and (0,1) and have a 
corresponding AUC(t) of 0.50 indicating that the model predicts no better than chance.   
Conversely, an AUC(t) of 1.0 would indicate perfect discrimination between women who 
develop breast cancer by time t and those who do not.  The c-statistic, which is a measure of the 
AUC, provides a global assessment of model performance over a given time frame.  In addition 
to time-specific ROC curves and AUCs, modified overall c-statistics were calculated for each 
model as estimates of concordance measures that are free of censoring and to provide inference 
regarding the difference between the models127.  ROC analyses and the global c-statistics were 
computed using R (version 2.13.2) packages written specifically for time-dependent outcomes 
with censored data126-128.     
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5.4 RESULTS 
 
The distributions of participant characteristics at entry by BI-RADS levels of breast density are 
presented in Table 1.  Women with high breast density were younger than those with less dense 
breasts.  The mean age in the highest breast density category was 57.0 years compared to 59.5 
years in the lowest density category.  Women with more dense breasts had a higher five-year 
predicted breast cancer risk (Gail score), but had a lower BMI.  The mean BMI decreased from 
33.0 in the lowest breast density category to 25.7 in the highest breast density category.  Women 
with dense breasts were also less likely to have a history of diabetes than those with less dense 
breasts.   
 There were a total of 349 cases of invasive breast cancer diagnosed.  Table 2 presents the 
distribution of cases by BI-RADS categories of breast density and ER-status.  The results of 
univariable and multivariable analyses are shown in Table 3 (top portion).  Baseline breast 
density was significantly associated with risk of invasive breast cancer.  When assessed 
univariably, the hazard ratio (HR) per increase of BI-RADS breast density category was 1.30 
with a 95% confidence interval (CI) of 1.12 to 1.51 (P<0.001).  Of all the possible explanatory 
variables assessed, only age, treatment, and years of smoking remained significant.  The HR for 
breast density after adjustment for the significant explanatory variables was 1.35 with a 95% CI 
of 1.16 to 1.58 (P<0.001).  The interaction between breast density and treatment was not 
significant (P=0.33, data not shown). 
 When breast density was added to a model with Gail score, both Gail score and breast 
density were significant (Table 3, bottom portion).  As the Gail score increased in increments of 
one percent, the HR was 1.13 (95% CI, 1.09–1.17; P<0.001).  The HR for breast density was 
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1.29 (95% CI, 1.11–1.50; P<0.001) per increase of BI-RADS density category.  Adjustment for 
the significant explanatory variables had negligible effects on the results for Gail score and 
breast density.  The resulting HR for Gail score was 1.11 (P<0.001) and the HR for breast 
density was 1.33 (P<0.001).  Figure 2 shows the time-specific ROC curves at year five for the 
models with breast density only, Gail score only, and Gail score and breast density.  The AUC 
for the model with breast density only was 0.55 indicating low discriminatory accuracy not much 
better than chance.  When considering the other two models, the AUC improved from 0.63 for 
the model with Gail score only to 0.64 when considering Gail score and breast density.  The 
overall c-statistic throughout the first five years of follow-up was 0.627 for the model with Gail 
score only and 0.633 when breast density was added.  The difference of 0.005 was not 
statistically significant (95% CI, -0.016–0.027).   
 There were 255 cases of ER-positive breast cancer.  Based on Chlebowski’s abbreviated 
model, we ran a proportional hazards model for ER-positive invasive breast cancer with the 
variables of age, number of relatives, and number of breast biopsies (Table 4).  Breast density 
significantly added to this abbreviated model (P=0.02).  The HR for breast density was 1.24 with 
a 95% CI of 1.03 to 1.49.  Among our data, the number of relatives was not significant in this 
model.  We therefore ran a model excluding this variable, but the effects on breast density were 
negligible (HR, 1.24; 95% CI, 1.04–1.49; P=0.02).  Breast density had very little effect on the 
discriminatory accuracy of the Chlebowski model with a time-specific AUC at year five of 0.60 
for both the original model and the Chlebowski model plus breast density (data not shown).   
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5.5 DISCUSSION 
 
In this study of postmenopausal participants of a chemoprevention clinical trial with an increased 
risk for developing breast cancer, we found that the BI-RADS classification of breast density at 
entry was directly and significantly associated with the risk of invasive breast cancer.  This 
association persisted when adjusting for important explanatory variables and when accounting 
for the calculated probability of developing breast cancer in the next five years based on the Gail 
model.  Despite this significance, we found that the BI-RADS classification of breast density did 
not appear to predict breast cancer risk much better than chance, and considering breast density 
in conjunction with the Gail score only slightly improved model discrimination. 
The Gail model has been validated and performs well in predicting the incidence of 
breast cancer in the population as a whole.  However, its modest discrimination indicates that it 
is not as good at predicting whether any given individual will develop breast cancer and should 
not be considered a tool of diagnostic screening.  Thus the Gail model is limited to the extent to 
which it identifies a meaningfully frequent category of high risk women who might uniquely 
benefit from one the preventive interventions currently available.  Identifying new risk factors 
and improving risk prediction models remains a high priority in breast cancer prevention and risk 
reduction.  Previous research has found promising results regarding the inclusion of breast 
density in risk prediction models.  Using data from the Breast Cancer Detection Demonstration 
Project, Chen and colleagues77 added a continuous measure of breast density to a model with 
weight, age of first live birth, number of affected relatives, and number of breast biopsies.  They 
reported improved risk discrimination with this new model when compared to the Gail model 
with increases in concordance ranging from 0.01 to 0.09 across the seven 5-year age groups that 
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they studied.  Three other studies29,78,79 used data from over one million women from seven 
mammography registries of the Breast Cancer Surveillance Consortium (BCSC).  All three 
reported modest improvement in predictive accuracy after adding breast density to the models 
with increases in c-statistics ranging from 0.01 to 0.03.   
Although breast density was significantly related to breast cancer risk, the HRs in our 
study were smaller than in previous studies.  When comparing the highest breast density group to 
the lowest group the HR was 2.15 (data not shown) compared to a three to five-fold increased 
risk of breast cancer as previously reported28-30.  One reason for our findings may be that our 
population consists only of high-risk women.  It could be that breast density does not provide as 
much of an improvement in risk prediction for those already at an increased risk based on other 
risk factors.  Also, our population received chemopreventive therapy for five years, which 
substantially reduced the risk of breast cancer, and may also have affected breast density.  Prior 
studies have reported a decrease in breast density over time with the use of tamoxifen129-132.  We 
did not have the ability to assess breast density over time because submitted copies of the 
mammogram reports were not required for all participants during follow-up.  Nevertheless, 
underlying changes in breast density due to treatment could have changed individual risk over 
time in a way that we could not measure.  The current study found only a slight increase in 
predictive accuracy when considering breast density in conjunction with the Gail score.  The 
modest improvements, however, are not surprising.  Although a two-fold increased risk with 
breast density is substantial, modeling has shown that risk factors with relative risks of at least 20 
may be needed to show significant improvements in predictive accuracy79,133,134. 
The current study has some limitations.  First, the only measure of breast density 
available was the BI-RADS category assigned by radiologists at each clinical site, and therefore 
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was not assigned on the basis of a standardized procedure.  The breast density categories may 
have been more accurate if we were able to collect the actual mammographic films and have an 
independent radiologist evaluate each film.  Furthermore, computer-aids that quantitatively 
calculate the percent of dense breast tissue in relation to the whole area of the breast, or those 
that take the thickness of the breast into account to calculate volumetric breast density are 
believed to be more precise and reproducible methods for measuring breast density28,52,56.  
However, these methods can be costly and perhaps not appropriate for widespread use.  Another 
criticism may involve the relationship between breast density and BMI.  Since BMI is positively 
related to total breast area, which is the denominator for percent breast density, women with high 
BMI are more likely to have a low percent breast density57.  Therefore, since a high BMI may 
increase breast cancer risk, it is believed that the effect of percent breast density on risk will tend 
to be underestimated when not adjusted for BMI58.  However, in our study, BMI was not 
associated with an increased risk for breast cancer and furthermore, adjusting for BMI had 
negligible effects on our HR estimate for breast density.  Another concern when studying breast 
density is the possibility of masking bias because prevalent cancers at the time of an initial 
mammogram could remain undetected in women with very dense breasts.  However, prior 
studies have shown that the bias effect is only small and short-lived28,52.  Particularly, one study 
looked at the site of dense tissue compared to the site of subsequent breast cancer and found that 
density in the cancer region of the breast was not a significant risk factor, thereby providing 
suggestive evidence that masking bias is not responsible for the density/breast cancer 
relationship53. 
This study provides further evidence that mammographic breast density is significantly 
associated with invasive breast cancer by evaluating the relationship among high-risk 
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postmenopausal participants in a clinical trial with clearly defined and accurately measured 
exposures and endpoints.  BI-RADS breast density was significant when considered in 
conjunction with the Gail score, but provided only slight improvement in discrimination for 
predicting the incidence of invasive breast cancer.  It also added significantly to Chlebowski’s 
abbreviated model for predicting ER-positive invasive breast cancer.  The BI-RADS 
classification system is a quick and readily available method for assessing breast density for risk 
prediction evaluations; however, future studies should focus on more accurate techniques for 
measuring breast density which may provide greater magnitudes of model improvement that 
could justify the inclusion of breast density in existing breast cancer risk prediction models. 
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5.6 TABLES AND FIGURES 
 
 
Table 5-1. Participant characteristics upon entry to the NSABP STAR trial for women 
included in the analyses 
Participant Characteristic 
 
BI-RADS Breast Density  
Fatty Scattered Heterogeneously Extremely 
P value 
No. (%) No. (%) No. (%) No. (%) 
Age       
    < 50    106 (9.9) 263 (8.2)  801 (9.9) 123 (11.7) <.001 
    50-59 439 (41.1) 1,507 (47.2) 4,194 (51.8) 607 (57.9)  
   ≥ 60 522 (48.9) 1,421 (44.5) 3,108 (38.4) 318 (30.3)  
Treatment      
    Tamoxifen 534 (50.0) 1,630 (51.1) 4,001 (49.4) 510 (48.7) 0.36 
    Raloxifene 533 (50.0) 1,561 (48.9) 4,102 (50.6) 538 (51.3)  
No. 1° relatives with BC      
    0 222 (20.8)    827 (25.9) 2,447 (30.2) 379 (36.2) <.001 
    ≥ 1 845 (79.2) 2,364 (74.1) 5,656 (69.8) 669 (63.8)  
No. previous breast biopsies      
    0 566 (53.0) 1,315 (41.2) 2,662 (32.9) 244 (23.3) <.001 
    1 284 (26.6)    958 (30.0) 2,547 (31.4) 311 (29.7)  
    > 1 203 (19.0)    879 (27.5) 2,811 (34.7) 476 (45.4)  
    Unknown 14  (1.3)   39 (1.2)    83 (1.0) 17 (1.6)  
5-year predicted BC risk (%)b      
     ≤ 2.00 153 (14.3)    382 (12.0)    891 (11.0)    102 (9.7) <.001 
     2.01-3.00 375 (35.1)    992 (31.1) 2,431 (30.0) 277 (26.4)  
     3.01-5.00 298 (27.9) 1,031 (32.3) 2,546 (31.4) 359 (34.3)  
     ≥ 5.01 241 (22.6)    786 (24.6) 2,235 (27.6) 310 (29.6)  
Body Mass Index (kg/m2) a      
    < 25.0 109 (10.2)    687 (21.5) 2,784 (34.4) 559 (53.4) <.001 
    25.0–29.9 305 (28.6) 1,087 (34.1) 2,866 (35.4) 303 (28.9)  
    ≥ 30.0 653 (61.2) 1,417 (44.4) 2,453 (30.3) 185 (17.7)  
History of Diabetes      
     No 965 (90.4) 2,972 (93.1) 7,670 (94.7) 1,014 (96.8) <.001 
     Yes    102 (9.6)  219 (6.9)   433 (5.3)    34 (3.2)  
History of Smoking (years)      
     None  601 (56.3) 1,740 (54.5) 4,565 (56.3) 596 (56.9) 0.002 
     < 15    103 (9.7)    417 (13.1) 1,060 (13.1) 133 (12.7)  
     15-34 217 (20.3)    680 (21.3) 1,663 (20.5) 226 (21.6)  
     ≥ 35 138 (12.9)    330 (10.3)  759 (9.4) 88 (8.4)  
     Unknown   8 (0.7)    24 (0.8)   56 (0.7)   5 (0.5)  
Total 1,067 3,191 8,103 1,048  
 
a There was one participant for whom BMI was unknown. 
b Determined by the Gail model.    
Abbreviations: BI-RADS, Breast Imaging Reporting and Data System; BC, breast cancer.  
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Table 5-2. Distribution of invasive breast cancer cases by breast density category and ER-
status 
BI-RADS Breast Density 
ER-Status 
Total 
Negative Positive Unknown 
    Almost entirely fatty (<25% dense) 5 14 0 19 
    Scattered fibroglandular densities (25-50% dense) 16 47 4 67 
    Heterogeneously dense (50-75% dense) 51 169 4 224 
    Extremely dense (>75% dense) 11 25 3 39 
Total 83 255 11 349 
 
Abbreviations: BI-RADS, Breast Imaging Reporting and Data System; ER, estrogen receptor. 
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Table 5-3. Breast density and incidence of invasive breast cancer 
Breast Density 
 HRa 95% CI P value 
Model 1    
Breast density 1.30 1.12 – 1.51 <.001 
Model 2b    
Breast density 1.35 1.16 – 1.58 <.001 
Gail Score + Breast Density 
 HRa 95% CI P value 
Model 3  
Breast density 1.29 1.11 – 1.50 <.001 
Model 4b    
Breast density 1.33 1.14 – 1.55 <.001 
 
a Reference group for breast density was “Almost entirely fatty” 
b Adjusted for age (continuous), treatment (tamoxifen, raloxifene), and years of cigarette 
smoking (none, <15, 15-34, 35+ yrs).  Those with unknown smoking status were excluded from 
analyses. 
Abbreviations: HR, hazard ratio; CI, confidence interval. 
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Table 5-4. Breast density and Chlebowski's abbreviated model for ER-positive invasive 
breast cancer 
Variables HRa 95% CI P value 
Age 1.03 1.02 – 1.05 <.001 
No. 1° relatives with breast cancer 0.82 0.62 – 1.08 0.17 
No. previous breast biopsies b 1.27 1.08 – 1.50 0.004 
Breast density 1.24 1.03 – 1.49 0.02 
 
a HR for age is per one year increase; reference groups for number of relatives and breast 
biopsies were “0”; reference group for breast density was “Almost entirely fatty”   
b Those with unknown biopsy data were excluded from analyses. 
Abbreviations: HR, hazard ratio; CI, confidence interval; ER, estrogen receptor. 
 
  
  82 
 
 
Figure 5-1. CONSORT diagram 
  
Randomly Assigned to STAR 
19,747 
 
Eligible with Follow-up 
19,490 
 
Mammogram Reports Reviewed 
18,544 
 
Included in Analysis 
13,409 
 
254  Without Follow-up 
    3  Not at Risk for Breast Cancera 
5,135  No Breast Density information  
           on Mammogram Report 
946  Non-English or Unavailable  
        Mammogram Report 
a History of bilateral mastectomy or invasive breast cancer prior to randomization. 
  83 
 
 
Figure 5-2. Estimated ROC curves and corresponding AUC at year 5 for models with BI-
RADS breast density only, Gail score only, and Gail score and BI-RADS breast density 
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6.1 ABSTRACT 
 
Results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer 
Prevention Trial (P-1) demonstrated a 49% reduction in invasive breast cancer incidence with 
tamoxifen use compared to placebo.  In addition, results indicated a statistically significant 
reduction in total osteoporotic fractures including those of the hip, spine, and Colles.  The current 
study assessed whether the effect of tamoxifen on fracture incidence was consistent across 
different categories of fracture risk for both osteoporotic and all clinical fractures.  The analysis 
included 13,207 women randomly assigned to 20 mg per day of tamoxifen or placebo for five 
years.  There was no evidence of an overall reduction in clinical fractures with tamoxifen therapy 
compared to placebo.  However, a differential benefit from tamoxifen was identified for women 
with and without a history of osteoporosis (Pinteraction=0.04).  Tamoxifen reduced the incidence of 
clinical fractures by 35% among those with a history of osteoporosis (HR, 0.65; 95% CI, 0.45-
0.93), but had no effect among those without a history of osteoporosis.  When considering 
osteoporotic fractures, there was a reduction with tamoxifen in all subgroups examined.  
However, the only differential benefit from tamoxifen was based on a history of bone fractures 
(Pinteraction=0.03), with a significant reduction occurring among those with no history of fracture 
(HR, 0.49; 95% CI, 0.31-0.75).  Women at high risk for developing breast cancer who are 
considering tamoxifen use for breast cancer risk reduction will gain the added benefit of fracture 
risk reduction, especially those who have a history of osteoporosis or no prior fracture.    
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6.2 INTRODUCTION 
 
Each year in the United States, approximately 1.5 million older people experience fractures 
because their bones have become weak, mostly due to osteoporosis135.  The risk for osteoporosis 
is highest among women and increases with age.  The risk for developing breast cancer among 
women also increases with age.  Therefore, multifactorial approaches to prevention in which 
multiple endpoints are considered when assessing an individual’s risk to benefit balance are 
desirable136.  Selective estrogen receptor modulators (SERMs) have been developed in an effort 
to reduce the risk of multiple conditions affecting aging women, including breast cancer, 
cardiovascular disease, and vertebral and nonvertebral fractures.   
Tamoxifen is a SERM that binds to the estrogen receptor and inhibits estrogen like 
activity in the breast.  In 1998, results from the National Surgical Adjuvant Breast and Bowel 
Project (NSABP) Breast Cancer Prevention Trial (BCPT, P-1) were released indicating a 49% 
reduction in the incidence of invasive breast cancer with tamoxifen compared to placebo.  In 
2005, updated results indicated that the effect persisted through seven years of follow-up80,87.  
Tamoxifen was the first of two drugs to be approved by the US Food and Drug Administration as 
a preventive therapy for breast cancer for high risk women, and remains the only drug approved 
for use in premenopausal women.  Although tamoxifen had unfavorable toxicity results 
regarding endometrial cancer and thromboembolic events, results of P-1 also indicated a 
reduction in total osteoporotic fractures including those of the hip, spine, and Colles.  The current 
study evaluated this relationship further to determine whether the effect of tamoxifen on 
fractures was consistent across different categories of fracture risk for both osteoporotic and all 
clinical fractures.  
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6.3 METHODS 
 
6.3.1 Overview 
 
P-1 was a multicenter, double-blinded, placebo-controlled, randomized clinical trial.  The 
primary aim of P-1 was to determine whether 20 mg per day of tamoxifen administered for five 
years reduced the incidence of invasive breast cancer.  Secondary endpoints included the 
incidence of noninvasive breast cancer, other invasive cancer, cardiovascular disease, stroke, 
deep vein thrombosis, pulmonary embolus, and bone fractures.  Institutional review boards at 
each clinical center approved the protocol, and all participants provided written informed 
consent. 
Between June 1, 1992 and September 30, 1997, 13,388 women were enrolled in P-1 at 
131 clinical centers throughout North America.  Each woman was randomly assigned to receive 
either placebo or tamoxifen for five years.  To evaluate eligibility, participants were required to 
complete a risk assessment form that gathered information regarding current age, race, age at 
menarche, age at first live birth, number of previous breast biopsies, presence of atypical 
hyperplasia, and number of first-degree relatives with a history of breast cancer.  Using these 
responses, the 5-year predicted breast cancer risk (Gail score) was centrally calculated by the 
NSABP Biostatistical Center62,64.  Eligible women had to be at least 35 years of age with no 
history of invasive breast cancer.  Women were also required to have a high risk for developing 
breast cancer, defined as having a history of lobular carcinoma in situ, being age 60 years or 
older, or having a minimum Gail score of at least 1.66%.  Women were excluded from P-1 if 
they had previously undergone a bilateral or unilateral prophylactic mastectomy.  Women were 
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also required to discontinue all use of estrogen or progesterone replacement therapy, oral 
contraceptives, or androgens for at least three months before random assignment.  Further details 
regarding accrual, study design, other inclusion and exclusion criteria, and main results of P-1 
have been published elsewhere80,87.   
 
6.3.2 Assessment of risk factors for osteoporosis 
 
Information about medical and behavioral history was collected at baseline.  Participants 
completed questionnaires upon entry into the trial that assessed their history of medical 
conditions (e.g., bone fractures, osteoporosis, and diabetes) and medication use (e.g., estrogen, 
oral contraceptives, thyroid replacement medication, cholesterol lowering agents, and calcium 
supplements).  They also completed a series of questions that assessed smoking status, alcohol 
use, leisure time physical activity levels, and menopausal status.  Alcohol use was calculated as 
the average number of drinks per day by combining information reported separately regarding 
the amount and frequency of beer, wine, and liquor consumption.  Menopausal status was 
inferred from questions about menstrual history.  A woman was considered postmenopausal if 
she reported that her menstrual periods had stopped for at least 12 months or that both of her 
ovaries had been removed.  For women with missing information or those who underwent a 
hysterectomy before entry but had at least one intact ovary and were menstruating at the time of 
the hysterectomy, menopausal status was classified on the basis of age at entry.  Women younger 
than age 50 were classified as premenopausal, and women age 60 or older were considered 
postmenopausal.  We could not confidently make assumptions based on age for women 50-59 
years and consequently, their menopausal status at entry was considered unknown for this 
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evaluation.  Each participant’s height and weight were measured and recorded by clinical staff 
members at each participating clinical center during a baseline clinical examination.  These 
measurements were used to calculate body mass index (BMI; kg/m2). 
 
6.3.3 Fracture outcomes 
 
Participants were followed every six months for the first five years and annually thereafter.  Staff 
members from participating clinical centers were responsible for performing participant follow-
up and were required to submit documentation, including a case report form as well as a 
confirmatory radiology report, for all bone fractures experienced during follow-up.  The 
documentation was reviewed centrally by trained medical professionals at the NSABP to confirm 
each fracture.  Although, information for all bone fractures was collected, it was decided a priori 
that fractures of the hip, spine and radius (Colles) would be studied as the primary fracture 
endpoints associated with osteoporosis.  The current study focuses on two primary endpoints: 
clinical fracture which includes all reported fractures except those of the skull, and osteoporotic 
fracture which only includes those of the hip, spine and Colles.  For women who experienced 
more than one fracture, only the first reported fracture was considered for these endpoints. 
 
6.3.4 Statistical analyses 
 
Data for the current study is based on the most recent update of the trial and comprises all data 
received and processed as of March 31, 2005.  Because follow-up was not required beyond seven 
years for the placebo arm, data is censored at seven years after the date of random assignment.  
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All analyses followed the intention-to-treat principle, and included all women for whom follow-
up data were available.  The flow of participants included in the current study is shown in Figure 
1.  A total of 13,207 women were included in the analysis; 6,610 assigned to placebo and 6,597 
assigned to tamoxifen.   
 Cox proportional hazards regression was used to estimate hazards ratios (HR) and 95% 
confidence intervals (CI) for tamoxifen versus placebo for all clinical fractures, all osteoporotic 
fractures, and hip, spine, and Colles fractures individually.  Cumulative incidence rates were also 
determined for each fracture outcome accounting for competing risk due to death, and 
differences between the cumulative incidence curves for each treatment group were assessed by 
the method of Pepe and Mori137,138.  Time to fracture for each fracture outcome was calculated as 
the time from random assignment to the date of first reported fracture.  If the participant did not 
experience the fracture outcome of interest, her time was censored on the date of death, date of 
last follow-up, or seven years after the date of random assignment based on which occurred first. 
For all clinical fractures and all osteoporotic fractures, we assessed whether the effect of 
tamoxifen differed by potential fracture risk factors with tests of interaction between the 
potential risk factor and treatment assignment.  We also computed the HR and 95% CI for 
tamoxifen versus placebo for each risk factor subgroup.  The subgroups were defined by age (35-
49, 50-59, ≥60 years), Gail score (≤2.00, 2.01-3.00, 3.01-5.00, ≥5.01), BMI (<25, 25-29.9, ≥30), 
menopausal status, smoking status (never or previously, current), alcohol use (none, 0-1 drinks 
per day, >1 drinks per day), leisure time physical activity (moderate to heavy, none to light), 
history of diabetes, history of bone fracture, history of osteoporosis, prior estrogen use, prior oral 
contraceptive use, use of thyroid replacement medication, use of cholesterol lowering agents, 
calcium supplement use, and summary fracture risk score (low, moderate, high).   
  91 
Summary fracture risk scores were calculated as a measure of osteoporotic fracture risk 
in this population, and were developed in the placebo group using logistic regression and 
previously published methods113,139,140.  Age, smoking status, physical activity, alcohol use, BMI, 
history of bone fractures, history of diabetes, history of osteoporosis, and prior use of estrogen, 
oral contraceptives, thyroid replacement medication, cholesterol lowering agents, and calcium 
supplements were assessed for inclusion in the risk factor set.  A backward elimination selection 
method was used based on a significance level of 0.05.  The final model included age, BMI, 
history of bone fractures, and history of osteoporosis.   A summary fracture risk score was then 
calculated using the coefficients from the final model and applying it to all participants from 
both treatment groups.  The area under the receiver operating characteristic curve (AUC) was 
0.76 (95% CI, 0.72-0.79) for osteoporotic fractures.  Based on summary fracture risk score, the 
participants were stratified into tertiles of low, moderate, and high risk for osteoporotic fracture.  
P values for all analyses were 2-sided using P<0.05 to determine statistical significance and all 
analyses were performed using SAS version 9.2 software (SAS Institute, Inc). 
 
 
6.4 RESULTS 
 
The mean age of participants included in this analysis was 53.9 years and 96% of the participants 
were white.  The majority were non-smokers (87% never smoked or quit smoking) and moderate 
drinkers (87% reported <1 alcoholic drink per day), and only 4.1% reported a history of diabetes.  
About 31% of participants reported a history of bone fractures whereas only 4.5% reported a 
history of osteoporosis.  Participant characteristics at entry were similar between those randomly 
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assigned to receive tamoxifen and those assigned to the placebo group (data not shown).  Table 1 
presents the distribution of participants by entry characteristics for women who experienced a 
clinical or osteoporotic fracture and those who did not.  Generally, women who experienced any 
clinical or osteoporotic fracture were older, more likely to have had a history of bone fracture 
and osteoporosis, and more likely to have used estrogen, thyroid replacement medication, 
cholesterol lowering agents, and calcium supplements.  They were also less likely to have used 
oral contraceptives.  Women who experienced an osteoporotic fracture during the study were less 
likely to have consumed more than one alcoholic drink per day and had a lower BMI.  The mean 
time of follow-up for all participants included in the analysis was 6.2 years. 
 
6.4.1 Clinical Fractures 
 
There was no evidence of an overall reduction in clinical fracture incidence with tamoxifen 
therapy.  A total of 747 (11.3%) women in the placebo group and 695 (10.5%) women in the 
tamoxifen group experienced a clinical fracture.  The HR comparing the tamoxifen group to the 
placebo group was 0.92 (95% CI, 0.83-1.03).  The cumulative incidence curves for clinical 
fractures by treatment group were similar (P=0.29, Figure 2).  The cumulative rate of clinical 
fracture at seven years was 126.9 per 1000 in the placebo group and 117.5 per 1000 in the 
tamoxifen group.   
 The hazard ratios and confidence intervals for comparing tamoxifen to placebo by the 
different risk factor subgroups for clinical fractures are presented in Table 2.  The interaction 
between treatment group and history of osteoporosis was the only interaction that reached 
statistical significance (P=0.04).  Tamoxifen reduced the incidence of clinical fractures by 35% 
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compared to placebo among those with a history of osteoporosis (HR, 0.65; 95% CI, 0.45-0.93), 
but had no effect among those without a history of osteoporosis (HR, 0.95; 95% CI, 0.86-1.06).  
Tamoxifen also appeared to have reduced the risk of clinical fractures compared to placebo for 
women who were age 60 years or older, postmenopausal, maintained moderate to heavy leisure 
time physical activity, previously used estrogen, did not ever use oral contraceptives, and had a 
high summary fracture risk score; but none of the interactions with treatment for these factors 
were statistically significant.   
 
6.4.2 Osteoporotic Fractures 
 
As previously reported in the update of the primary findings of P-1, tamoxifen was significantly 
associated with a reduction in total osteoporotic fractures compared to placebo87.  There were 
116 (1.8%) women with fractures of the hip, spine, and Colles in the placebo group and 80 
(1.2%) in the tamoxifen group (HR, 0.68; 95% CI 0.51-0.91).  There was a 32% reduction in 
fractures of the hip (HR, 0.68; 95% CI 0.41-1.15), a 25% reduction in fractures of the spine (HR, 
0.75; 95% CI 0.50-1.13), and a 31% reduction in Colles fractures (HR, 0.69; 95% CI 0.39-1.22).  
The cumulative incidence curves for all osteoporotic fractures combined and for hip, spine, and 
Colles fractures individually are shown in Figure 3.  The cumulative incidence for osteoporotic 
fractures was significantly lower for the tamoxifen group compared to placebo (P=0.002).  The 
cumulative rate of osteoporotic fracture at seven years was 19.8 per 1000 in the placebo group 
and 13.8 per 1000 in the tamoxifen group.  When examining the individual sites of osteoporotic 
fracture, the cumulative rate of fracture was consistently lower in the tamoxifen group than the 
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placebo group for all three sites; however, hip fracture was the only site for which the difference 
between cumulative incidence reached statistical significance (P=0.04).   
 Table 3 presents the results when examining osteoporotic fractures by risk factor 
subgroups.  The majority of these fractures occurred in women age 60 and older.  There was a 
reduction in osteoporotic fractures with tamoxifen compared to placebo in all subgroups 
examined; however, the only significant interaction was between treatment and history of bone 
fracture.  Tamoxifen reduced the incidence of osteoporotic fractures by 51% among those with a 
no history of bone fracture (HR, 0.49; 95% CI, 0.31-0.75), and by 9% among those with a 
history of bone fracture (HR, 0.91; 95% CI, 0.62-1.34).   
 
 
6.5 DISCUSSION 
 
In this population of healthy women at high risk for developing breast cancer, tamoxifen therapy 
significantly reduced the risk of osteoporotic fractures.  The results were consistent regardless of 
whether most risk factors were present or absent, with the exception of a history of bone 
fractures.  There was a slight but nonsignificant reduction in all clinical fractures with tamoxifen, 
and this effect was modified when considering a history of osteoporosis.    
 The relationship between tamoxifen and bone mineral density (BMD) has been 
extensively studied in the literature106.  Because of the estrogen-agonist effects on the bone, 
tamoxifen has been found to increase BMD and prevent bone loss among postmenopausal 
women with breast cancer receiving adjuvant treatment with tamoxifen.  However, since using 
fractures as an endpoint requires longer follow-up time and larger sample sizes than studies of 
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BMD, the subsequent effect of tamoxifen on fractures has not been studied as extensively.  The 
current study is the first to our knowledge to compare the relative effects of tamoxifen to placebo 
on fracture risk by subgroups of healthy women defined by potential fracture risk factors.   
Although tamoxifen has been shown to prevent bone loss in postmenopausal women, 
studies have found significant bone loss in patients who have remained premenopausal following 
preventive or adjuvant tamoxifen therapy for breast cancer107-109.  The different effects of 
tamoxifen by menopausal status have been attributed to the differing levels of endogenous 
estrogen before and after menopause.  Specifically, high premenopausal levels of estrogen may 
be modifying the sensitivity of the estrogen receptors in osteoblasts causing tamoxifen to have an 
antagonist effect before menopause compared to an agonist effect after menopause.  In our study, 
the data suggest that tamoxifen may reduce the incidence of clinical fractures among 
postmenopausal women only, but the interaction between treatment and menopausal status was 
not significant and so we cannot draw any definitive conclusions.  Furthermore, when 
considering osteoporotic fractures, we found no difference in the effect of tamoxifen by 
menopausal subgroups, and tamoxifen reduced the incidence of fractures in both pre- and 
postmenopausal women.   
When considering all clinical fractures, there was a significant reduction in risk with 
tamoxifen use among those with a history of osteoporosis and no effect among those without a 
history of osteoporosis.  When considering osteoporotic fractures, the hazards ratios showed a 
similar effect even though the interaction term was not significant.  Because a history of 
osteoporosis is often an indicator of increased risk of bone fracture, one would expect similar 
results among subgroups defined by history of bone fracture.  However, there was no difference 
in treatment effect for clinical fractures irrespective of bone fracture history, and the results for 
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osteoporotic fractures were different than one would expect with a greater reduction seen among 
those with no history of bone fracture.  A possible explanation for these results could be that the 
general question pertaining to a lifetime history of bone fractures may have captured other 
characteristics that affect a woman’s fracture risk (e.g., risk-taking personalities, athleticism, or 
clumsiness) that are different than osteoporosis-related factors.  Furthermore, when considering 
the summary fracture risk score which had good AUC, there was a significant reduction with 
tamoxifen in the highest fracture risk group.  This was inconsistent with the history of bone 
fracture findings and thus the significant association between no history of bone fracture and 
osteoporotic fractures may have been due to chance.   
There has been substantial interest in the development and implementation of risk tools 
designed to identify women who may be at greater risk for developing osteoporosis and 
fractures139,141-143.  Because P-1 was a breast cancer prevention trial and fractures were not the 
primary endpoint, we did not collect all of the variables typically included in the available risk 
tools.  However, we were able to calculate a summary fracture risk score for this analysis as a 
way to classify our population into groups of low, moderate, and high risk for experiencing an 
osteoporotic fracture.  Based on multiple risk factors that we had available, we were able to 
investigate whether those at high risk might benefit more from treatment with tamoxifen than 
those at lower risk.  However, the effect of tamoxifen on both clinical fracture risk and 
osteoporotic fracture risk was not significantly different between the risk groups.   
 The study design of the P1-trial is strong.  It was a randomized clinical trial conducted in 
a large population of healthy women, and all fracture endpoints were centrally reviewed and 
confirmed.  However, the primary study objective was the assessment of breast cancer risk and 
the study population was women at high risk for breast cancer development.  When used to 
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assess the risk of fractures, the P-1 trial is not without limitation.  Although the total number of 
clinical fractures was substantial, the numbers of fractures experienced within some of the risk 
factor subgroups were small and the numbers of individual fractures of interest (hip, spine, and 
Colles) were limited.  These limited numbers did not allow us to explore subgroup analyses by 
the individual types of osteoporotic fractures.  Additionally, when the initial results of P-1 were 
released and the trial was unblinded, about 32% of participants assigned to placebo crossed over 
to active treatment with tamoxifen.  Thus, the true effect of tamoxifen may be underestimated in 
this analysis.  Our results were also limited by the general definition that was used to define a 
clinical fracture event.  All clinical fractures other than those of the skull were considered, 
regardless of the cause of their occurrence; thus, we were unable to determine which fractures 
occurred due to an accident and which were likely due to weakened bones.  Another limitation is 
that our population consisted mostly of white women, and all participants were at high-risk for 
breast cancer.  Therefore our results may not be generalizable to other populations of women.  
Furthermore, we know that an increase in BMD is associated with an increased risk for breast 
cancer27.  We did not collect information on BMD in P-1, but since all women had an increased 
risk for breast cancer, they may also have had higher BMD than the general population.     
 This study elaborated on fracture findings from P-1, and showed that tamoxifen use 
significantly reduced osteoporotic fracture risk among healthy women at risk for developing 
breast cancer.  Subgroup analyses showed that the reduction was similar for both premenopausal 
and postmenopausal women, as well as most other subgroups of women based on potential 
fracture risk factors, except a history of bone fracture.  Our results also indicated the potential for 
a reduction in all clinical fractures with tamoxifen for women with a history of osteoporosis.  We 
know from current literature that tamoxifen is associated with increased BMD in postmenopausal 
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women, and this study supports the concept that this transfers into a reduction of osteoporotic 
fractures regardless of menopausal status.  Women at high risk for developing breast cancer, who 
are contemplating tamoxifen use for breast cancer risk reduction, will gain the added benefit of 
fracture risk reduction, especially those who have a history of osteoporosis or no prior fractures.    
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6.6 TABLES AND FIGURES 
 
 
Table 6-1. Percent distribution of participants by baseline characteristics for women with 
and without fractures 
Participant Characteristicb 
All Clinical Fractures Osteoporotic Fracturesa 
No Fracture 
(n = 11,765) 
Fracture 
(n = 1,442) 
No Fracture 
(n = 13,011) 
Fracture 
(n = 196) 
Tamoxifen group 50.2 48.2 50.1 40.8 
White race  96.3 97.7 96.4 96.9 
Postmenopausal 50.7 63.3 51.6 84.2 
Current smoker  12.8 10.4 12.5 14.3 
>1 alcoholic drinks per day  13.0 11.9 12.9 10.2 
None to light leisure time physical activity  54.1 54.8 54.3 50.0 
History of diabetes  4.0 4.6 4.0 6.1 
History of bone fracture  29.2 42.4 30.3 53.6 
History of osteoporosis  4.0 8.3 4.3 15.3 
History of estrogen use  33.4 40.5 33.9 52.0 
History of oral contraceptive use  61.4 54.4 61.0 38.8 
History of thyroid replacement medication 15.9 18.2 16.1 20.9 
History of cholesterol lowering agents  7.8 10.8 8.1 12.2 
History of calcium supplements 37.9 46.3 38.6 53.6 
Age (years)     
  35-49  40.5 29.2 39.7 11.2 
50-59 years  30.8 30.4 30.9 21.9 
≥ 60 years  28.7 40.4 29.4 66.8 
BMI (kg/m2)     
  < 25.0  38.9 37.0 38.6 45.9 
25.0-29.9  32.9 33.5 32.9 34.2 
≥ 30.0 28.2 29.5 28.5 19.9 
5-year predicted breast cancer risk (%)     
≤ 2.00 25.2 23.2 25.0 23.0 
2.01-3.00 31.2 29.9 31.1 30.1 
3.01-5.00 26.4 28.2 26.6 28.1 
≥ 5.01 17.2 18.8 17.3 18.9 
Summary fracture risk score     
Low 32.7 22.0 31.9 8.7 
Moderate 34.8 32.2 34.8 19.4 
High 32.5 45.8 33.4 71.9 
a Includes unduplicated count of hip, spine, and Colles fractures. 
b Denominators for percentages differ because of missing data. 
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Table 6-2. Number of clinical fractures and hazard ratios by treatment and risk subgroup 
Participant Characteristic at Baseline 
Placebo 
(n = 6,610) 
Tamoxifen 
(n=6,597) 
Hazard Ratioa 95%  CI 
P for 
interaction No. (%) No. (%) 
All participants 747 (11.3) 695 (10.5) 0.92 0.83 – 1.03 
 
Age (years)        
35-49 211 (8.1) 210 (8.1) 1.00 0.83 – 1.21  0.27 
50-59 219 (10.8) 219 (10.8) 0.98 0.81 – 1.18  
60+ 317 (15.9) 266 (13.5) 0.83 0.71 – 0.98  
5-year predicted breast cancer risk (%)        
≤ 2.00 171 (10.3) 163 (9.9) 0.96 0.78 – 1.19 0.80 
2.01-3.00 219 (10.8) 212 (10.3) 0.94 0.77 – 1.13  
3.01-5.00 213 (11.9) 193 (11.2) 0.95 0.78 – 1.15  
≥ 5.01 144 (12.9) 127 (10.8) 0.83 0.65 – 1.05  
BMI        
< 25.0 276 (10.9) 258 (10.0) 0.91 0.77 – 1.08 0.97 
25.0-29.9 254 (11.5) 229 (10.7) 0.93 0.78 – 1.11  
≥ 30.0 217 (11.6) 208 (11.0) 0.94 0.78 – 1.14  
Menopausal status        
Premenopausal 242 (8.2) 246 (8.4) 1.02 0.86 – 1.22 0.15 
Postmenopausal 450 (14.0) 390 (12.3) 0.87 0.76 – 0.99  
Smoking status        
Never or previously smoked 668 (11.6) 624 (10.9) 0.93 0.83 – 1.04 0.78 
Current smoker 79 (9.7) 71 (8.5) 0.89 0.64 – 1.22  
Alcohol Use        
None 166 (11.9) 142 (10.5) 0.88 0.71 – 1.11 0.91 
0-1 drinks per day 491 (11.3) 472 (10.7) 0.94 0.83 – 1.06  
>1 drinks per day 90 (10.4) 81 (9.7) 0.93 0.69 – 1.25  
Leisure Time Physical Activity        
Moderate to heavy  352 (11.7) 300 (9.9) 0.83 0.71 – 0.97 0.06 
None to light  395 (11.0) 395 (11.1) 1.01 0.88 – 1.16  
History of diabetes        
No 716 (11.3) 660 (10.4) 0.92 0.83 – 1.02 0.62 
Yes 31 (11.9) 35 (12.6) 1.04 0.64 – 1.69  
History of bone fracture        
No 431 (9.4) 400 (8.7) 0.92 0.80 – 1.05 0.84 
Yes 316 (15.6) 295 (14.6) 0.94 0.80 – 1.10  
History of osteoporosis        
No 676 (10.7) 647 (10.3) 0.95 0.86 – 1.06 0.04 
Yes 71 (24.2) 48 (16.2) 0.65 0.45 – 0.93  
History of estrogen use        
No 434 (9.9) 424 (9.8) 0.99 0.86 – 1.13 0.12 
Yes 313 (14.0) 271 (11.9) 0.83 0.71 – 0.98  
History of oral contraceptive use        
No 353 (13.5) 304 (11.8) 0.85 0.73 – 0.99 0.15 
Yes 394 (9.9) 391 (9.7) 0.99 0.86 – 1.14  
History of thyroid replacement medication        
No 603 (10.9) 577 (10.4) 0.94 0.84 – 1.06 0.40 
Yes 144 (13.1) 118 (11.4) 0.84 0.66 – 1.07  
History of cholesterol lowering agents        
No 672 (11.1) 614 (10.1) 0.90 0.81 – 1.01 0.21 
Yes 75 (13.7) 81 (15.3) 1.12 0.82 – 1.53  
History of calcium supplements        
No 392 (9.7) 382 (9.5) 0.97 0.85 – 1.12 0.28 
Yes 355 (13.8) 313 (12.2) 0.87 0.75 – 1.01  
Summary fracture risk score        
Low 156 (7.5) 161 (7.7) 1.01 0.81 – 1.26 0.21 
Moderate 233 (10.2) 232 (10.2) 1.01 0.84 – 1.21  
High 358 (15.9) 302 (13.5) 0.84 0.72 – 0.97  
    
a Hazard ratios for women in the tamoxifen group compared to women in the placebo group. 
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Table 6-3. Number of osteoporotic fractures and hazard ratios by treatment and risk 
subgroup 
Participant Characteristic at Baseline 
Placebo 
(n = 6,610) 
Tamoxifen 
(n=6,597) 
Hazard Ratioa 95%  CI 
P for 
interaction No. (%) No. (%) 
All participants 116 (1.8) 80 (1.2) 0.68 0.51 – 0.91 
 
Age (years)        
35-49 15 (0.6) 7 (0.3) 0.47 0.19 – 1.15 0.40 
50-59 22 (1.1) 21 (1.0) 0.93 0.51 – 1.70  
60+ 79 (4.0) 52 (2.6) 0.65 0.46 – 0.93  
5-year predicted breast cancer risk (%)        
≤ 2.00 23 (1.4) 22 (1.3) 0.97 0.54 – 1.73 0.14 
2.01-3.00 39 (1.9) 20 (1.0) 0.49 0.29 – 0.85  
3.01-5.00 29 (1.6) 26 (1.5) 0.93 0.55 – 1.58  
≥ 5.01 25 (2.2) 12 (1.0) 0.46 0.23 – 0.91  
BMI        
< 25.0 55 (2.2) 35 (1.4) 0.62 0.40 – 0.94 0.54 
25.0-29.9 41 (1.9) 26 (1.2) 0.65 0.40 – 1.06  
≥ 30.0 20 (1.1) 19 (1.0) 0.94 0.50 – 1.76  
Menopausal status        
Premenopausal 18 (0.6) 11 (0.4) 0.61 0.29 – 1.29 0.76 
Postmenopausal 91 (2.8) 63 (2.0) 0.69 0.50 – 0.96  
Smoking status        
Never or previously smoked 100 (1.7) 68 (1.2) 0.68 0.50 – 0.92 0.82 
Current smoker 16 (2.0) 12 (1.4) 0.74 0.35 – 1.56  
Alcohol Use        
None 32 (2.3) 23 (1.7) 0.75 0.44 – 1.27 0.80 
0-1 drinks per day 73 (1.7) 48 (1.1) 0.64 0.44 – 0.92  
>1 drinks per day 11 (1.3) 9 (1.1) 0.84 0.35 – 2.04  
Leisure Time Physical Activity        
Moderate to heavy  56 (1.9) 42 (1.4) 0.73 0.49 – 1.10 0.62 
None to light  60 (1.7) 38 (1.1) 0.64 0.42 – 0.95  
History of diabetes        
No 110 (1.7) 74 (1.2) 0.67 0.50 – 0.90 0.60 
Yes 6 (2.3) 6 (2.2) 0.92 0.30 – 2.86  
History of bone fracture        
No 61 (1.3) 30 (0.7) 0.49 0.31 – 0.75 0.03 
Yes 55 (2.7) 50 (2.5) 0.91 0.62 – 1.34  
History of osteoporosis        
No 96 (1.5) 70 (1.1) 0.72 0.53 – 0.98 0.33 
Yes 20 (6.8) 10 (3.4) 0.49 0.23 – 1.05  
History of estrogen use        
No 58 (1.3) 36 (0.8) 0.62 0.41 – 0.94 0.58 
Yes 58 (2.6) 44 (1.9) 0.73 0.50 – 1.09  
History of oral contraceptive use        
No 73 (2.8) 47 (1.8) 0.64 0.44 – 0.92 0.55 
Yes 43 (1.1) 33 (0.8) 0.76 0.48 – 1.20  
History of thyroid replacement medication        
No 93 (1.7) 62 (1.1) 0.66 0.48 – 0.90 0.55 
Yes 23 (2.1) 18 (1.7) 0.81 0.44 – 1.50  
History of cholesterol lowering agents        
No 102 (1.7) 70 (1.2) 0.68 0.50 – 0.92 0.88 
Yes 14 (2.6) 10 (1.9) 0.73 0.32 – 1.64  
History of calcium supplements        
No 51 (1.3) 40 (1.0) 0.78 0.52 – 1.18 0.38 
Yes 65 (2.5) 40 (1.6) 0.61 0.41 – 0.90  
Summary fracture risk score        
Low 11 (0.5) 6 (0.3) 0.53 0.20 – 1.44 0.58 
Moderate 20 (0.9) 18 (0.8) 0.91 0.48 – 1.72  
High 85 (3.8) 56 (2.5) 0.65 0.47 – 0.92  
 
  a Hazard ratios for women in the tamoxifen group compared to women in the placebo group. 
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Figure 6-1. CONSORT diagram 
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Figure 6-2. Cumulative incidence of all clinical fractures 
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Figure 6-3. Cumulative incidence of osteoporotic fractures by site of fracture 
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7.0 GENERAL DISCUSSION 
 
7.1 SUMMARY OF FINDINGS 
 
This dissertation evaluated important issues related to breast cancer risk reduction in women 
participating in two breast cancer chemoprevention clinical trials (BCPT and STAR) conducted 
by the NSABP.  Chapter 4 assessed women from both trials to determine whether BMI was 
related to the risk of invasive breast cancer among pre- and postmenopausal women.  Chapter 5 
evaluated the relationship between breast density and invasive breast cancer among STAR 
participants and assessed whether a common, one-time assessment of breast density would 
improve the predictability of the Gail model.  Chapter 6 investigated the reduction in risk of bone 
fracture, a concomitant benefit of tamoxifen, in BCPT participants to see whether the effect of 
tamoxifen on osteoporotic and all clinical fractures differed by fracture risk subgroups.  All 
participants analyzed were required to be at high-risk for developing breast cancer and were 
randomly assigned to receive either placebo or tamoxifen in BCPT, and tamoxifen or raloxifene 
in STAR.   
 The results presented in Chapter 4 indicated a statistically significant positive association 
between BMI and breast cancer risk among premenopausal women and no association among 
postmenopausal women.   Although the interaction between BMI and treatment was not 
significant, our results were suggestive that SERM therapy might attenuate the BMI/breast 
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cancer association among postmenopausal women.  We also found that BMI was more strongly 
associated with ER-positive cancer than with ER-negative cancer.   
 As shown in Chapter 5, the BI-RADS classification of breast density at entry was directly 
and significantly associated with the risk of invasive breast cancer when assessed in conjunction 
with the Gail score.  However, the addition of this measure of breast density only slightly and 
nonsignificantly improved model discrimination.  The BI-RADS classification of breast density 
had similar effects when added to Chlebowski’s abbreviated model for predicting ER-positive 
invasive breast cancer only.   
Lastly, as presented in Chapter 6, tamoxifen therapy significantly reduced the risk of 
osteoporotic fractures, regardless of whether most risk factors were absent or present, with the 
exception of a history of bone fracture.  Women with no history of a prior bone fracture 
experienced a greater reduction in new osteoporotic fractures with tamoxifen use.  Although the 
overall reduction in all clinical fractures with tamoxifen was not statistically significant, the 
results supported the potential for a reduction in all clinical fractures among women with a 
history of osteoporosis.   
 
 
7.2 CONCLUSIONS AND PUBLIC HEALTH SIGNIFICANCE 
 
The overweight and obesity epidemic in the United States is an important public health 
challenge.  In addition to complications such as cardiovascular disease, type 2 diabetes, and 
osteoarthritis, excess weight has also been linked to an increased risk for breast cancer among 
postmenopausal women.  However, the relationship has remained unclear in premenopausal 
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women.  Our results for high-risk women participating in chemoprevention clinical trials were 
inconsistent with some of the previous findings reported in the literature.  This inconsistency 
suggests that the relationship between BMI and breast cancer may not be the same for all 
women.  More studies are needed to clarify the relationship between excess weight and the risk 
of invasive breast cancer by menopausal status, and future research may focus on different 
markers for high body weight as well as changes in weight over time.  However, in this 
population, overweight and obesity were not protective among premenopausal women, and 
instead significantly increased breast cancer risk.  This is important since body weight is a 
modifiable risk factor.  Currently, overweight and obesity are only listed as risk factors among 
postmenopausal women, which may give the impression to premenopausal women that they do 
not need to be concerned about excess weight.  However, our results suggest that all women at 
high risk for developing breast cancer should strive to achieve and maintain a healthy weight. 
Mammographic breast density is an established risk factor for breast cancer.  Our 
findings provided further evidence that mammographic breast density is significantly associated 
with invasive breast cancer among high-risk postmenopausal participants.  However, the BI-
RADS measure of breast density did not significantly improve discrimination for predicting 
invasive breast cancer incidence compared to the Gail score alone.  There is currently debate in 
the clinical setting about whether breast density should be used as a marker for more extensive 
breast cancer screening.  Although our findings do not definitively support either side of the 
argument, this simple one-time assessment of breast density does not appear to predict breast 
cancer risk much better than chance, and does not seem to provide further predictability beyond 
the factors already assessed in the Gail model.  The BI-RADS classification system is a quick, 
inexpensive, and readily available method for assessing breast density for risk evaluations; 
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however, future studies should focus on newer, more accurate techniques for measuring breast 
density as well as changes in density over time.  These methods may provide greater magnitudes 
of model improvement that could potentially justify the inclusion of breast density in existing 
models for breast cancer risk prediction. 
 According to the 2004 Surgeon General’s Report on Bone Health and Osteoporosis, 
approximately 1.5 million older people each year experience fractures because their bones have 
become weak, and the medical costs for treating those broken bones is estimated at $18 billion 
each year.  Since the risk for both osteoporosis and breast cancer among women increases with 
age, interest among researchers and clinicians has shifted to multifactorial approaches to 
prevention.  We have learned from previous research that tamoxifen is associated with an 
increased BMD in postmenopausal women, and this study supports that tamoxifen also leads to a 
reduction of osteoporotic fractures regardless of menopausal status.  Therefore, women with or at 
risk for osteoporosis who are using tamoxifen for breast cancer risk reduction will receive the 
additional benefit of fracture risk reduction. 
Breast cancer incidence and mortality rates have been slowly declining in the US; 
however, breast cancer remains the most frequently diagnosed cancer and the second leading 
cause of cancer death among women.  Therefore, breast cancer prevention remains an important 
area of research.  We must be able to accurately identify high-risk women, and also provide safe 
options for lowering their risk.  If modifiable risk factors such as excess body weight are present, 
then based on our results, all women regardless of menopausal status should be advised to 
maintain a healthy lifestyle through diet and exercise.  On the other hand, if a woman’s increased 
risk is based on risk factors that are not easily modifiable, such as those included in the Gail 
model, then more complex methods for lowering risk such as tamoxifen or raloxifene therapy 
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may be recommended.  However, these drugs have been associated with side effects, and so we 
must accurately predict who is high-risk and would likely benefit from preventive therapy to the 
best of our ability.  Mammographic breast density has been considered for inclusion in the Gail 
model; but, our results showed that the BI-RADS measurement was not favorable for predictive 
improvements. Therefore, the Gail model remains the gold standard for assessing non-genetic 
breast cancer risk.  Despite the acceptance of the Gail model by clinicians and the success of 
chemopreventive therapies in lowering breast cancer risk, few high-risk women are actually 
choosing to use tamoxifen or raloxifene.  While we are trying to determine the reasons for this 
reluctance and identify other agents with fewer side effects, we hope that providing more 
knowledge about these drugs, such as their combined benefits on the bone and the breast, may 
help to encourage their use.   
The analyses discussed in this dissertation helped to clarify and expand information 
surrounding some important issues in breast cancer prevention.  Advancement in breast cancer 
risk reduction, including the refinement of important risk factors and preventive therapies, may 
help to continue the decline of breast cancer incidence and mortality in the US.   
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